



El titulo de la tesi: In-silico methods to
drug discovery

El subtitulo de la tesi: Cancer

Autor: Francisco Martínez Jiménez

TESI DOCTORAL UPF / ANY L'any de la tesi: 2016


DIRECTOR DE LA TESI

Director: Marc A. Marti-Renom Departament Departament:
Biomedicine





A mi madre.



Agradecimientos Agraeixo....




Abstract

This is the abstract of the thesis in English. Please, use less than 150 words.

Resum

Vet aqui el resum de la tesi en catala.



Prefaci



Contents

Index of figures	xvi
-------------------------	------------

List of tables	xvii
-----------------------	-------------

0.0.1	Protein structure	2
0.0.2	Protein function	17
0.0.3	Protein-Ligand Interactions	18
0.1	Drug discovery	25
0.1.1	Computational drug discovery	28
0.2	Drug discovery in Tuberculosis	32
0.2.1	Research strategies against MTB.	36
0.3	Targeted cancer therapies	39
0.3.1	Monoclonal antibodies	40
0.3.2	Small molecule kinase inhibitors	42

0.3.3	Resistance to targeted cancer therapies	50
-------	---	----


List of Figures

1	Hierarchical distribution of layers in protein structure . .	4
2	The original plot of the relation of residue identity and the r.m.s. deviation of the backbone atoms of the common cores of 32 pairs of homologous proteins. Figure extracted from [5]	5
3	a) Growth of released structures per year. Data extracted from PDB. b) Pie chart with the percentage of structures determined by the different methods. Data extracted from PDB.	10
4	Workflow in comparative protein structure modeling. The figure has been extracted from [28]	12
5	Homology threshold curve as a function of alignment length. Data extracted from [31]	16
6	Schematic representation of three popular protein-ligand binding theories.	20

7	Drug discovery and development pipeline. For each stage the average cost and time are included. Post-approval times not included in the time-line. Data extracted from [117].	27
8	Cost of developing a new drug. Blue bars indicate expenses in clinical phases while red represents expenses in pre-clinical stages. Costs are shown in \$ millions. Data extracted form: Tufts Center for the Study of Drug Development (http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study). . .	28
9	Estimated worldwide TB incidence rates in 2014. Figure extracted from [145].	35
10	3D structure of ABL1 kinase in complex with imatinib displaying the different structural regions of protein kinases. The structure represents the typical kinase inactive DGF-out conformation. The protein is represented as ribbons and the ligand as sticks. The activation loop is coloured in cyan, the DGF motif in blue, the P-loop is coloured in red, the hinge region in purple and the α C helix in green. PDB accession code 2HYY.	44
11	Structural features of the canonical classes of small molecule kinase inhibitors. The center panel shows the main interaction sites of different inhibitors types. The side panels show the specific structural features of each of the binding modes. Figure extracted from [192].	47

List of Tables

1	List of the public Protein Modeling Tools	17
3	FDA approved kinase inhibitors alongside their pharmacological target, binding mode and year of FDA approval.	48



Summary

sencillo

Consta de

tesi-upf.cls book

1. Es redissenya la portada `\maketitle`).
- 2.
3. Es redefineix `cleardoublepage` para que las paginas en blanco no se numeren

Preamblel

paquets `crop i geometry`.

Taules Includes `figure i un tabular`

Index

1. lo llamas en preambulo `\usepackage{makeidx}` `\makeindex`
con esto lo imprimes `\printindex` con esto lo creas `makeindex`

Introduction

Protein are essential molecules

The importance of proteins in biological chemistry is just reflected by their name, derived from the Greek word *proteios*, and that means ”of the

first rank”¹. Their presence is so essential that they constitute most of the cell dry mass [1]. They are not only the cell’s building blocks, but also they perform nearly all the cell’s functions. Some roles of proteins include serving as structural components of cells and tissues (e.g., *keratin* or *collagen*), transmission of information between cells by hormones such as the *insulin* or the *oxytocin*, facilitating the transport and storage of small molecules (e.g., the transport of oxygen by *hemoglobin*) or providing a defense against foreign invaders (e.g., antibodies). Other proteins such as the *actin* and the *myosin* are responsible of muscle contraction and therefore our movement. However, the most fundamental role of proteins is their ability to act as enzymes, which, catalyzes most of the chemical reactions in biological systems. In summary, proteins are crucial macromolecules present in most of the processes carried out by the cell and, in spite of being extensively studied for many years, they still carry many unanswered questions.

0.0.1 Protein structure

A protein is a molecule made from a long chain of amino acids linked thorough a covalent peptide bond. Proteins are therefore also known as *polypeptides*. Attached to this repetitive chain are those portions of the amino acids that are not involved in the covalent bond, the **side chains**. Side chains confer the different physico-chemical properties of each of the 20 types of amino acids [2]. The composition of the amino acid sequence determines the function and the structure of a protein. That is because

¹The term protein was coined by Jons Jacob Berzelius in 1838. It was first used by Gerardus Johannes Mulder, advised by Berzelius, in its publication *Bulletin des Sciences Physiques et Naturelles en Néerlande (1838)*. pg 104. *SUR LA COMPOSITION DE QUELQUES SUBSTANCES ANIMALES*, where he observed that all proteins seemed to have the same empirical formula and came out to the erroneous idea that they might be composed of a single type of very large molecule. Berzelius proposed the name because the material seemed to be the primitive substance of animal nutrition that plants prepare for herbivores.

the unique sequence creates a specific pattern of attractive and repulsive forces between amino acids along the polypeptide that leads to a folding process resulting in a specific three-dimensional structure. These forces are usually non-covalent interactions between the side chains of the amino acids. Non-covalent interactions are weaker than covalent ones, allowing the folded structure to certain degree of conformation mobility i.e: to be dynamic. This phenomenon is really important to facilitate the interaction with other molecules as we will explore further in 0.0.3.

Protein structures are complex conformation of atoms organized in a hierarchical manner 1. The first level of this hierarchy, referred to as the **primary structure**, is the ordered sequence of amino acids of the polypeptide. Certain segments of these chains, tend to form simple shapes such as helices, strands, turns or loops. These folding patterns are referred to as secondary elements and collectively constitute the **secondary structure** of the protein. The two most frequent type of secondary elements are the α -helixes and the β -sheets [3]. The overall chain tends to fold further into a three-dimensional **tertiary structure**. Contrary to the secondary structure, the tertiary structure folding is driven by interactions from amino acids far apart in the primary sequence. The tertiary structure, is generally the most stable form of the protein, that is, the one that minimizes its free energy [4]. Furthermore, the tertiary structure is also the biologically active form of the protein, and its unfolding usually leads towards partial or total inactivation of the protein. Finally, some proteins are composed by multiple folded chains. In such cases, each folded subunit folds independently and then joins the others forming a biologically active complex. This type of organization is considered as the **quaternary structure**.

This traditional paradigm of protein structure has been challenged by some exceptions of proteins that lacks of a fixed or ordered three-dimensional structure. The intrinsically disordered proteins (IDPs) cover a wide spectrum of states from fully unstructured to partially structured including conformations such as *random coils* or *molten globules*. Moreover, some factors may lead to the permanent loss of structure of a protein, and when




Figure 1: Hierarchical distribution of layers in protein structure

that occurs, they endanger the entire organism. How problematic protein misfolding can be for the organism is illustrated by examples such as cystic fibrosis, Alzheimer's, Parkinson's and Huntington's diseases.

Figure 2 from the seminal paper [5] shows the correlation degree to which protein structures changed as a function of sequence divergence. This work helped to set up the fundamentals of what is considered a central paradigm in protein evolution: protein structure is more conserved than sequence. However, not all the regions in a protein structure are equally conserved. It's been shown that functionally important amino acids, responsible of the interaction with other molecules, are more conserved than the rest of the protein structure [6]. Additionally, the structural core is more conserved than the surface [7]. The high conservation of the core enables the protein to maintain the global shape, while the surface is free to change (i.e. to mutate) some functional features [8]. These evolutionary mechanisms are in accordance with the central *sequence* \rightarrow *structure* \rightarrow

function paradigm that prevails in the protein evolution field.




Figure 2: The original plot of the relation of residue identity and the r.m.s. deviation of the backbone atoms of the common cores of 32 pairs of homologous proteins. Figure extracted from [5]

Protein Structure Determination

Since in 1960, the British biochemist John Kendrew determined the myoglobin structure [9], more than 37,000 different protein structures have been deposited in the Protein Data Bank (PDB) [10]. The PDB is a repository created in the 1970s with the aim of storing all the 3D protein structures and unifying their format. Figure 3a shows the variation of the number of deposited structures over the time. The number of PDB structures has significantly been increased over the last years thanks to initiatives such as the Protein Structure Initiative (PSI) [11] or the structural genomics [12]. The later, was born with the aim of determining the

structure of all human proteins. However, soon after, they realized that the goal was unrealistic. Fortunately, the number of folds which represent the complete *fold space* observed in nature is much smaller than the number of proteins. Therefore, the current goal is to determine the structure of a representative set of proteins, that is, at least one protein per fold class. Once it is known the structure of one representative protein, and thanks to the *homology modeling* methods [0.0.1], it is usually feasible inferring the structure of other proteins belonging to the same fold class as we will explore further in the next section [0.0.1].

Several methods are currently used to experimentally determine the 3D structure of a protein. More than 99% of structures deposited in the PDB have been determined by the three main methods: X-ray crystallography, nuclear magnetic resonance spectroscopy (NMR) and electron microscopy (EM) (Figure 3b). These methods provide experimental data that helps the scientist to elucidate the final structure of the protein. However, in most cases, the experimental data is not sufficient by itself to build an atomic model from scratch. Additional knowledge about the molecular structure must be added. For example, the preferred geometry of atoms in a standard protein, the patterns of repulsion and attraction of amino acids, etc. All this information allows the building of the final model that is consistent with both the experimental data and the prior knowledge of the 3D geometry of the molecules. We next briefly explain the three aforementioned methods:

- (a) **X-ray crystallography.** Currently, it is the most widely used method in protein structure determination. Almost 90% of the structures deposited in PDB come from X-ray crystallization (Figure 3b). In this method, X-rays fired at a crystal of the molecule are diffracted by the electron clouds of the atoms in the crystal, forming a unique pattern that is printed as a picture of the atomic density map. Subsequently, the diffraction pattern is combined with other physiochemical knowledge of the protein, such as composition or atomic geometrical restrictions, in order to build the final 3D model [13].

Before the X-ray exposition, it is then necessary a prior step of crystallization of the molecule. Unfortunately, the crystallization step introduces itself a great number of limitations. The flexibility of proteins is one of the these limitations. The flexible nature of proteins makes really difficult the creation of an accurate and homogeneous alignment of multiple molecules used to create the crystal. Another important limitation is the different conditions required for crystallizing each different molecule. These limitation are especially noteworthy in membrane proteins. Despite of nearly 30% of eukaryotic proteins are membrane proteins, only 604 unique membrane protein structures have been solved to date (data extracted from <http://blanco.biomol.uci.edu/mpstruc/>; March 2016). As a consequence, alternative innovative developments are needed to overcome the numerous obstacles associated with X-ray structure determination of membrane proteins [14].

The accuracy of the final atomic structure relies on the quality of the generated crystals. Two important measures of the accuracy of a crystallographic structure are its atomic *resolution*, which refers to the smallest separation between crystal lattice planes that is resolved in the diffraction pattern [15], and the *R-factor*, which measures how well the refined structure predicts the observed data [16].

- (b) **NMR spectroscopy.** The NMR spectroscopy technique has been used for years to determine the structure of proteins. Currently, almost 10% of the structures deposited in PDB have been determined by this method (Figure 3b). In NMR spectroscopy, the protein is purified, placed in a strong magnetic field, and eventually probed with radio waves. The observed set of atomic resonances is then analyzed to retrieve a list of atomic nuclei that are close in the space. Similarly to X-ray crystallography, this set of restrains is subsequently used to build the structural model of the protein that contains the 3D conformation of each atom in the space [17].

NMR spectroscopy has a major advantage over X-ray crystallog-

raphy: it provides information on proteins in solution. Therefore, this method is the main method for studying the atomic structure of highly flexible proteins. A standard NMR structure includes an ensemble of protein structures, all of them being consistent with the experimentally observed set of restraints. The ensemble of structures are very similar in those regions with strong restraints, less constrained regions of the proteins, on the other hand, show less agreement in the generated models. These lack of restriction areas are presumably the flexible regions of the protein since they do not provide a strong signal in the experiment.


A big limitation in comparison with X-ray crystallography is its applicability: this technique is usually limited to proteins smaller than 35 kDa. Moreover, NMR can only be applied to soluble proteins that do not aggregate and are stable during the NMR experiment [17, 18]. NMR is also inherently insensitive and milligram amount of proteins are required [18]. All these limitations have hampered the broader use of this technique narrowing down the cases where this method is fruitful.

- (c) **Electron microscopy** methods. EM methods are emerging as a very versatile tool for determining the structure of large macromolecular complexes. To date, less than 1% of proteins in PDB have been determined by EM methods (Figure 3b). However, in recent years there has been dramatic increase in the number of complexes determined by EM technologies. The *revolution* in the structural biology field is perfectly manifested by the cryo-electron microscopy (cryoEM) method: in 2015 alone, cryoEM was used to map the structures of more than 100 different molecules [19]. In cryoEM a beam of electrons is fired at a frozen protein solution. The emerging scattered electrons pass through a lens to create a magnified image on the detector, and the structure can then be deduced afterwards.


The utility of cryoEM and others EM tools lies on the fact that it allows the observation of molecules that have not been fixed in any

way, showing them in their native environment. This is the opposite of the crystallization step in X-ray crystallography, which many times hampers the success of the whole procedure. CryoEM have been traditionally used in large molecules such as ribosomes[20] or the V-ATPase[21], but they have also shown their potential in small membrane proteins[22] and medically important proteins[23].

However, there are still a room for further improvement in EM technologies. Despite of recent advances in the resolution, most of the cryoEM structures have lower resolution than the X-ray ones. Furthermore, there are numerous technical unsolved problems that need to be addressed to make easier its standardization and systematical application. Finally, the high prize of cryoEM experiments are many times slowing Its spread and therefore, there is a need to reduce cost in order to make it globally accessible.



(a)



(b)

Figure 3: a) Growth of released structures per year. Data extracted from PDB. b) Pie chart with the percentage of structures determined by the different methods. Data extracted from PDB.

Protein Structure Prediction

Despite of the advances in methods for protein structure determination, most of the known proteins lack of structure in the PDB. There are 550,740 annotated and curated protein sequences in UniProtKB (<http://www.uniprot.org>, April 2016). However, only 4% of them (23,195 different protein sequences) have a link to a PDB structure. Therefore, there is a gap between the number of known protein sequences and the number of determined structures: the *sequence-structure gap*. Computational methods for structure determination are helping to bridge this gap. The prediction of the 3D structure of a protein from its amino acid sequence has always been one of the most desirable goals in computational biology. It would save a lot of resources, and it would set a milestone in the structural biology field. Unfortunately, we are still far from being able to predict the structure of any protein from its primary sequence. Overall, four different approaches are commonly used. The first, and most extensively used, is the *homology* or *comparative* modeling, that uses similar experimentally determined structures to model the structure of the protein of interest [24, 25]. Second, *fold recognition* and *threading* methods are used to model protein structures with low similarity to known protein structures [24, 25]. Third, *de novo* or *ab initio* methods make their predictions by combining the principles of physics that rule protein folding, with information derived from known structures but without relying in any type of similarity or evolutionary relationship to known folds [26]. Finally, the *integrative* or *hybrid* methods combines different computational and/or experimental sources to perform the structure prediction [27].

Homology modeling

This type of protein structure prediction methods exploits the evolutionary relationship between the *target* protein (i.e. protein being modeled) and the *template(s)* with known experimental structure. They are based on

Figure 4: Workflow in comparative protein structure modeling. The figure has been extracted from [28]

the biological premise that evolutionary related sequences tend to have similar 3D structures. Figure 4 shows the regular steps in comparative protein structure modeling:

1. **Identification of suitable template structures related to the target protein.** This step consist on a search for similar sequences with known 3D structure. This task is easy when a close homologue of the target protein has been solved. Initiatives such as the PSI[11] are helping in this issue increasing the number of modellable proteins. However, there are still many proteins with lack of homologous proteins in PDB. In these cases, alternative methods such as *ab initio* modeling should be used.
2. **Alignment between the target and the template(s) sequence(s).** The sequence identity of the target-template alignment is the most frequently used measure for similarity. Consequently, the sequence identity is also a good predictor of the final 3D model quality. The overall accuracy of models calculated form alignments with sequence identity higher than 40% is usually good (i.e. RMSD² lower than 2.0Å). In the 30%-40% identity range, errors can be more severe and are often locate in loops and highly flexible regions. Below the 30% of sequence similarity, often referred to as *twilight region*, serious errors occurs including the basic fold being mis-predicted [29, 30]. Figure 5 shows an empirical threshold for homology modeling extracted from [31]. The region below the curve covers those cases where the alignment does not carry enough information to model the 3D structure, while area above the threshold curve, include those cases where homology modeling is appropriate.

3. Modeling of the structurally conserved regions and prediction

²Root Mean Square Deviation is the measure of the average distance between the atoms of two superimposed proteins. Equation $RMSD = \sqrt{\frac{1}{N} \sum_{i=1}^N \delta_i^2}$ where δ_i is the distance between the N_i pair of equivalent atoms (usually the $C\alpha$).

of the structurally variable regions.. There are different algorithms to assign the spatial coordinates of the target protein using the template(s)-target alignment information. Highly conserved regions are generally well modeled, while those regions with insertions or gaps are more prone to include errors and sub-optimal atomic orientations.

4. **Refinement of the initial model.** In this step the model is refined to idealize bond geometry and to remove errors that may have been introduced in the modeling step. The refinement process pursues the free energy minimization of the generated 3D protein model. Many different algorithms have been applied to perform the minimization step: molecular mechanics force fields [32], molecular dynamics [33], Monte Carlo [34] and Genetic Algorithms[35] are just several examples of the multiple approaches applied in this issue.
5. **Evaluation of the model(s).** Model evaluation seeks for the identification of the different errors that might have occurred during the modeling process. Multiple methods have been developed to assess the quality of a 3D model. In fact, 3D model assessment has a very such productive field for many years that it was included in the seventh edition of the CASP experiment [36]. The general question of how accurate is a model can be reformulated in several specific questions:
 - i *Is the selected fold correct?* The fold assessment consist of deciding whether a given protein model has the right fold. Residue-based combined accessible surface and distance-dependent scoring functions have shown the best performance in this task [37].
 - ii *How do we select the best model among the set of decoys or alternative solutions?* Several models can be generated by making changes in the template-target alignment, by selecting different template(s) structure(s) or by using different seeds in the refinement non-deterministic algorithms. Atom-based

distance-depend scoring functions have proved to be useful for this particular task in some cases[38]. However, there is not a gold standard for ranking the generated 3D models. Thus, the model selection eventually relies on the expertise of the person running the modeling.

- iii *Which is the overall accuracy of the model? Which is the accuracy of the model in a particular region of the model?* These questions can be addressed by defining scores that correlates with the RMSD after superimposing a model and its native structure. Numerous scoring functions have been implemented to address this issue. Some of them, the *physics-based scoring functions*, attempt to approximately calculate the atomic interaction energies in the system. These scoring functions usually encode a set of parameters that describes the energy of a system of particles. Examples of these scoring functions are AMBER[39], CHARMM[40] or MM-PDBSA[41]. Differently the *knowledge-based potentials* or *potentials mean force* are scoring functions derived from an analysis of empirical information. Although the obtained scores are often considered approximations of the free energy, this physical interpretation is incorrect [42]. Nevertheless, since they frequently correlate with the actual free energy differences, they have been broadly used with significant success [43, 44, 45].

The application of comparative modeling is limited by several aspects. The first one, is the availability of a suitable template. Despite of the efforts made to determine at least one structure per known fold [11], divergences between the template and the target hampers the modeling of a correct 3D structure. In fact, models based on alignment below 30% have been shown to be unsatisfactory 5. The lack of template problem is even more noticeable in membrane proteins. The limited number available known membrane proteins structures makes its modeling an extremely difficult task. However, the high value of these proteins in diverse therapeutic areas [46, 47], is fostering the development of specific membrane




Figure 5: Homology threshold curve as a function of alignment length. Data extracted from [31]

protein modeling methods [48]. Another aspect that restricts the success of homology modeling is the innate flexibility of proteins. Highly flexible regions are more difficult to model and consequently are more prone to errors than more rigid parts of the structure. Despite of these limitations, homology modeling has been successfully applied to many proteins and its currently the main approach to computationally model the 3D structure of proteins³.

There are many computational methods for predicting the 3D structure of proteins. Table 1 shows some of the most famous ones alongside its websites and references. Each of these methods have their own strengths and weakness and none of them clearly outperforms the others for every case. In my case, I have used Modeller because it is the one we are more familiar with.

³For a comprehensive review of homology modeling methods, applications and limitations please consider [49, 50]

Modeling Tool	Website	Reference(s)
Modeller	https://salilab.org/modeller/	[28, 51]
SwissModel	http://swissmodel.expasy.org	[52]
HHPred	http://toolkit.tuebingen.mpg.de/hhpred	[53]
I-Tasser	http://zhanglab.ccmb.med.umich.edu/I-TASSER/	[54, 55, 56]
Rosetta	http://rosetta.bakerlab.org/	[57]
RaptorX	http://raptorx.uchicago.edu/	[58]
3DJIGSAW	http://bmm.crick.ac.uk/~3djigsaw	[59]
WhatIf	http://swift.cmbi.ru.nl/whatif/	[60]

Table 1: List of the public Protein Modeling Tools

0.0.2 Protein function

The major question in the protein biology field has been to understand the protein sequence-structure-function relationship. It is known that structure of a protein determines its biological function. However, different *regions* of the structure can perform semi-indepent functions from each other. These regions are referred to as **protein domains**. A domain is substructure produced by any part of polypedtide chain that can fold independently into a compact and stable structure [61, 62, 63]. Domains on average contain 80-250 residues [64]. Estimates of the number of domains per protein say that more than 70% of procaryotik proteins and 80% of eukaryotic proteins include more than one domain [65, 66]. Among this multi-domain proteins, 95% of them contains only two to five protein domains [65]. Domains are not only the basic functional units of proteins, but also the evolutionary units of protein evolution. As proteins have evolved, domains have been modified and combined to build new proteins [67, 68]. Such is the importance of domains in protein evolution, that they have been included in current protein classification methods as one of the major classification parameters. Some of these domain classification methods such as SCOP [69] or CATH [70] are purely based on the structure, while others such as Pfam [71] or INTERPRO [72] include information about the function in their classification.

Domains, and consequently proteins, perform its biological activity by interacting with other molecules. Proteins can interact with other proteins, constructing a protein-protein complex, with ions or with small-molecules. The substance that is bound to the *target* protein is called the **ligand**, while the region of the protein where the ligand is binding is called ligand’s *binding site*⁴. The next section is focused on protein-compound interaction and it presents the basis for all the work developed during the thesis.

0.0.3 Protein-Ligand Interactions

The roles played by the protein ligands are diverse. Catalysis of enzyme substrates, regulation of the protein activity, cellular communication or defense from external attackers are just few some examples of the multiple functions that small-molecule ligands perform in living organisms. All these functions are performed by small-molecules that selectively bind their *target* proteins. However, given the vast amount of proteins and small-molecule ligands in the cytoplasm, how do the small-molecule ligands select their protein targets? There has been several protein-ligand binding theories. In the *Lock and key Theory* [73], Emil Fischer proposed a system where the binding sites of enzymes are rigid and pre-adjusted geometrically to the natural substrate 6a. This theory became widely accepted for years. Nevertheless, during subsequent years, evidence started to accumulate suggesting that the binding sites of proteins do not match perfectly their ligands, but rather the binding process triggers some conformational changes in the enzyme. Therefore the obsolete Lock and key model was replaced by the *Induced fit theory* [74]. The induced fit theory proposes that initially enzymes do not perfectly match their substrate geometrically. However, the binding-process triggers a set of conforma-

⁴For simplicity, in this manuscript, unless otherwise indicated, the term ligand will only refer to small molecules ligands, while proteins ligands will be explicit named as protein-protein interactions

tional changes in the protein binding site that improves the match 6b. More recently, another theory called the *Monod-Wyman-Changeux model* or *MWC model* came up[75]. This theory contends that proteins are able to shift spontaneously between multiple conformations called *sub-states*[76, 77]. This model could also explain *allostery*, a phenomenon in which the binding of the molecule to the catalytic site is affected the binding of other ligand to a different site. This theory has undergone some changes and the current accepted theory posits that ligands bind preferentially to one of the conformation sampled spontaneously by the protein, and therefore stabilizes it. It means that, by changing the protein’s energy landscape, ligands change a less favorable conformation into the most favorable one. This model does not necessarily refute the induce fit theory since in many cases, the restrains applied by the ligand on the binding site is expected to induce some conformational changes that will further stabilize the interaction [78, 79].

Protein-ligand binding energetics

The high variety of functions that ligands perform by binding to proteins its also reflected in the diversity in its binding affinity. Binding energies usually range from -2.5kcal/mol to -22kcal/mol [80]. The binding strength displayed by proteins matches the biological goal of the binding. For instance, ligands involved in protein communication tend to bind weakly to enable a quick state switch. Cofactors binding to enzymes, on the other hand, tend to bind strongly to their targets. The negative sign of the values reflects that is a favorable binding that releases energy: *the binding free energy*. This energy can be measured experimentally, thorough the equilibrium constant of the binding, or it can be calculated computationally. Equations 1 and 2 shows, under thermodynamic equilibrium conditions, the relationship between the Gibbs free energy or binding affinity and the equilibrium constant of the binding. R is the ideal gas constant [ref], T is the temperature , $[C]$ the complex concentration and



(a) Fischer's *lock and key model*. The protein is represented in green and the ligand in red. The ligand's binding site of the protein matches the ligand perfectly.



(b) Koshland's *induced fit model*. The protein is represented in green and the ligand in red. The overall shape of the ligand matches the binding site. The ligand bindings causes some conformational changes that improves the interaction.



(c) *MWC model's* representation. The protein changes its conformation constantly (one color per conformation), with at least one these conformation matching the ligand. Its binding triggers some conformational changes that improves the protein's energy landscape.

Figure 6: Schematic representation of three popular protein-ligand binding theories.

$[P]$ and $[L]$ the protein and ligand concentration respectively.

$$\Delta G = -RT \ln K_{bind} \quad (1)$$

$$K_{bind} = \frac{[C]}{[P] * [L]} \quad (2)$$

These equations show that the binding free energy can be measured experimentally. However, in many cases the experimental measurement are unfeasible or very difficult due to technical problems. Additionally, the expenses associated with these experiments often restricts its broader application. In such cases, computational methods to calculate the free binding energy are needed. The calculation of binding free energy have acquired a remarkable importance in the drug discovery field where the calculation of ligand-target affinity is crucial for the pre-clinical phase 0.1. Unfortunately, its calculation its a extremely challenging task. The main points that should be addressed to accurately calculate the binding free energy are:

1. **The free energy of binding 1 is the difference of two large energies.** The energy of the complex (E_{pl}) and the energy of the unbound partners ($E_p + E_l$) 3:

$$\Delta G_{bind} = E_{pl} - (E_p + E_l) \quad (3)$$

2. **There are two opposite and complex energies driving the process.** The binding enthalpy (ΔH_{bind}) and the loss of entropy of both the ligand and the protein (ΔS_{bind}):

$$\Delta G_{bind} = \Delta H_{bind} - T \Delta S_{bind} \quad (4)$$

3. **Non explicit representation of the energetic interactions of the system.** Small-molecule binding events on a protein cavity implies the displacement of solvent molecules (usually water molecules).

The energy generated by the this exclusion of water molecules is the main driving force in ligand-protein binding [81]. Unfortunately, explicit representation and simulation of all the forces involved this event is computationally unfeasible. A popular approach to model is to use implicit solvent theories [82, 83, 84], where the water molecules are represented as a continuous medium instead of individual explicit molecules. The implicit solvation model is justified in liquids, where the potential of mean force are applied to approximate the behavior of many highly dynamic solvent molecules. However, there could be other medias with specific solvation or dielectric properties that are continuous, but not necessarily uniform, since their properties can be described by different analytic functions [85]. Within the most famous implicit models we can find those based on those based on Boltzmann theory (PB) [86] and those based on Generalized-Born (GB) approximation [87].

Hydrogen bonds and salt bridges between the ligand and the protein can also be a source of free energy gain upon ligand binding. This energy gain comes from the displacement of water molecules bound to the protein. The net gain of energy upon hydrogen bond is around 1-2 kcal/mol. Some scoring functions treat all hydrogen bonds equally, while others, distinguish between neutral and charged ones. Other energies that could be modeled and that contribute to the binding affinity calculations are those generated by interactions with metal ions [88]. However, because there can be a covalent component in this type of interactions, its overall binding energy contribution is difficult to model. Finally, nonspecific van der Waals and hydrophobic interactions are also included in some methods as additional energy contributors to the overall free energy of binding [89].

One of the main applications of binding free energy calculation is predicting whether a ligand is binding a particular protein target. In other words, given the predicted binding free energy determine whether a specific compound targets a specific protein binding site. In the next sec-

tion we will explore further these and other approaches aiming at protein-compound interaction prediction.

Protein-ligand prediction

⁵ The importance of ligand-protein interaction prediction is reflected by the large number of available methods that use multiple different approaches [90, 91]. We can distinguish between *free structure* methods (i.e. methods that do not rely on the protein structure to perform its predictions) and *structure-based* methods.

Free structure methods do not require the protein structure to perform their predictions. They usually use prior knowledge on protein compound interactions, to further extend the interactions to new and unseen compounds. The development of these methods can be split in two phases. The first step consist on the creation of a predictive model that uses a collection(s) of protein-compound interactions to learn hidden relationships between compound and their protein targets. In the second step, these predictive models are used to extrapolate this knowledge to new and unseen compounds (or targets). The extrapolation relies on different types of compound or protein similarity. Knowledge-based free structure methods have been assisted by the advent of new and powerful *high-throughput screening methods* (HTS) that allowed the creation of large computational compound-protein databases such as ChEMBL [92], Therapeutic Target Database (TTD) [93], Binding MOAD [94], BindingDB [95], PubChem [96, 97] or ZINC [98]. The recent growth of these collections is accordingly improving these method’s accuracy and coverage. Moreover, since they do not rely on protein structure they can be theoretic-

⁵In chapter [REF] we present nAnnolyze, a method for protein-ligand interaction prediction. In the introduction of the presented manuscript, there is a discussion of the current state-of-the-art methods in protein-ligand interaction prediction. Therefore, this section is focused in explaining the classification, underlying basics and (dis)advantages of the different approaches.

cally applied to any protein or any compound. Nevertheless, free structure methods do not provide detailed information about the ligand-protein relationship. Information such as binding localization, type of interaction (i.e. allosteric, on-target or off-target) or predicted free energy of binding; that is absolutely essential in the drug discovery process. Consequently, free structure methods are mostly employed in very early stages of the drug discovery pipeline.

Structure based target prediction methods use the protein structure to determine whether a small-molecule interact with a protein target. Docking methods have traditionally dominated the structure-based target prediction field. Virtual docking consist on predicting the preferred orientation of one molecule (the ligand) to a second (the protein) one. The process of finding the best orientation of molecule (i.e. its *pose*) to its protein target is not simple, since several entropic, enthalpic and environmental factors have an impact on the interactions between them 0.0.3. The underlying idea of this approach is to generate a comprehensive set of ligand-protein conformations, and then to rank them according to a specific scoring function [99]. The importance of virtual docking methods is not only reflected by the large number of published methods (AutoDock [100, 101], DOCK [102], FLEXX [103], GOLD [104] and GLIDE [88] among others), but also by their success in drug discovery applications [105, 106, 107]⁶. However, virtual docking methods also have some limitations. The most apparent one is that they do rely on protein structure. As explained above 0.0.1 the coverage of the human structural proteome is below 40%. Thus, some of the most interesting targets in drug discovery lack of experimentally determined 3D structure. In addition to these structurally inherent problems and despite of some massive applications [109], virtual docking methods are still computationally very expensive. Additionally, they need the prior knowledge of the binding localization in the protein surface which many times is unknown before the screening. To overcome the computational limitations, new structure-based meth-

⁶For a comprehensive review of virtual docking methods an applications please consider [108]

ods use the so-called *comparative docking* approaches that solely rely on structural comparisons, both of compounds and protein targets, to infer new interactions [REFS]. Chapter [REF nAnnolyze] presents nAnnolyze, a method to predict ligand-target interactions using a comparative docking approach. In that chapter it is further discussed the applications and limitations of these type of approaches.

0.1 Drug discovery

Drug discovery is the process by which potential new potential medications are discovered. It involves a wide range of scientific disciplines, including biology, chemistry, pharmacology and recently also the computational branches of these fields. Historically, drugs were discovered through the identification of the active ingredient from traditional remedies or by serendipitous discovery. Later, the development of synthetic methods allowed the generation of purely synthetic structures that were not found in nature and that were investigated as potential therapeutic agents. More recently, the advent of new genomics, proteomics and high throughput screening (HTS) techniques, resulted in the identification of large number of novel targets for future drug research. In addition to this *technological revolution*, the advances in bioinformatics and system biology field has prompted the change in drug discovery paradigm towards a more target-centric approach. This *modern drug discovery paradigm* usually implies the screening of thousands of molecules in order to identify those that have the desirable therapeutic effect in the previously validated protein target [110, 111]. Figure 7 shows the current drug discovery pipeline alongside the estimated cost and time of each of the phases. Most modern drug discovery programs begin with the identification of a bio-molecular target which pharmacological intervention is theoretically beneficial for the treating disease. A target is a broad term which can be applied to a range of biological entities which include proteins, DNA and RNA. The target needs to be accessible to the putative drug molecule(s),

this property is called as *target druggability*. Wrong selection of the target (i.e. weak association between the target and the treating disease) implies lack of the expected efficacy, which is the most important cause of project failure in clinical trials[112, 113]. During the *Target-to-hit* stage, the target is screened against a set of candidate molecules seeking for the identification of those which able to perform the desired therapeutic activity. Alternatively, in some cases the first step of the discovery process is based on a *Phenotypic screening* of a collection of molecules. This screening pursues the identification of those molecules that perform a predefined function in a biological model. In any case, prior knowledge of the biomolecular target of the therapeutic activity is generally associated with better outcomes in clinical trials [114]. However, there are various drugs in the market with unknown *mechanism of action* (i.e. the drug target is still unknown) [115], most of them coming from the traditional drug discovery paradigm. After this hit(s)⁷ identification, in the *hit-to-lead* stage, molecular hits are evaluated and undergo limited optimization to identify promising lead compounds for further stages. The optimization to convert a hit to a lead molecule, implies several properties. Properties such as the potency, the selectivity or the pharmacokinetics (PK) properties [hablar en computational methods, SAR]. These lead compounds undergo more extensive optimization in a subsequent step of drug discovery called lead optimization (LO). The main goal of this stage is to maintain favorable properties in lead compound(s) while improving on deficiencies in the lead structure(s). Finally, the selected lead(s) enters into the preclinical stage where the main goals are determining the safe dose for *First-in-man study* and the first assessing the product’s safety profile. Estimates say that, on average, of every 5,000 to 10,000 compounds that begins the pre-clinical stage, only one becomes an approved drug [116].

According to the The Tufts Center for the Study of Drug Development (<http://csdd.tufts.edu>), the development and marketing

⁷ A hit compound could have several definitions. Here we use the one from [114] where they defined a hit as being a compound which *has the desired activity in a compound screen and whose activity is confirmed upon retesting*




Figure 7: Drug discovery and development pipeline. For each stage the average cost and time are included. Post-approval times not included in the time-line. Data extracted from [117].

approval for a New Molecular Entity (NME) takes more than 13 years and around \$2.6 billion ⁷. In fact, the cost of developing a new drug has dramatically increased since the 1970s ⁸. Currently, the cost of developing a NME is more than two times the 1990s one, and more than ten times of the cost in the 1970s. This raise in the drug development cost has lead to a dramatic shrinkage of the efficiency, measured in terms of the number of new approved drugs per billion US dollars of research and discovery (R&D) spending [118]. Both research and development phases have significantly raised their expenses ⁸. Factors that have contributed to the raise of clinical costs include increased clinical trial complexity, larger clinical trial size, greater assessment of safety and toxicity drug profiles or evaluation on equivalent drugs to accommodate payer demands for comparative effectiveness data [118]. Similarly, factors such as the complexity of the target disease, expenses associated with the application of high-throughput technologies or the increased complexity of mechanism of action are boosting the prizes of pre-clinical stages. However, pre-clinical associated expenses could be narrowed down with a rational use of the state-of-the-art technologies. In this matter, computational methods are emerging as a tool to speed-up by allowing the management of the massive amount of data generated during the discovery stages. The

next section presents different computational methods currently applied during the drug discovery pipeline.




Figure 8: Cost of developing a new drug. Blue bars indicate expenses in clinical phases while red represents expenses in pre-clinical stages. Costs are shown in \$ millions. Data extracted from: Tufts Center for the Study of Drug Development (http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study).

0.1.1 Computational drug discovery

Over the last thirty years, computer-aided drug discovery (CADD) methods, have played a key role in the development of therapeutic drugs [119]. The modern drug discovery pipeline includes multiple CADD approaches that assist during the drug discovery process:

1. **Target identification and validation methods.** Many different computational approaches are used to identify and validate new targets. The *the genomics revolution* caused by New-Generation Sequencing methods (NGS) have boosted the development of methods that primary rely on the genetic association between targets and the treating diseases. Sometimes, these data is combined with additional information that allows a better evaluation of the target viability. This complementary information include structural data, such as experimental structure availability or druggability assessment; system-biology information such as protein-protein interactions, protein pathway analysis or sub-celullar target localization [120]. Recently, the inclusion of pharmacological data by *drug reporpousing or repositioning* methods is becoming very popular [121, 122, 123]. These methods uses information of whether the protein is targeted by any FDA approved drug. This information is used then to prioritize those targets with annotated FDA approved drug(s). Such drug(s) are subsequently applied to the treating disease to validate the target testing hypothesis. Computational methods for target identification and validation have applied in great variety of diseases: from infectious diseases such as Tuberculosis [124] or Malaria [125], cancer [126] to neurogeneretive diseases [127].
2. **Ligand-target prediction.** Once the target has been validated, CADD methods can help in the search of potential target hits. This is one of fields where CADD methods have been more successful either by making the predictions from scratch or in combination with phenotypic screenings [128]. Section 0.0.3 specifies the different methods and its current applications.
3. **Quantitative structure-activity relationship (QSAR).** QSAR is an approach designed to find relationships between chemical structure and the biological activity of small molecules. QSAR methods are based on the assumption that variations in the biological activity of a series of chemicals targeting a particular protein are correlated

with variations in their structural, physical, and chemical properties [129]. QSAR methods have become an essential tool in the pharmaceutical industry where they play a major role in the hit-to-lead and lead optimization stages. Traditionally, these methods have been used to improve compounds bioactivity. Recently, the applications have been extended to the improvement of ADMET (adsorption, distribution, metabolism, elimination, toxicity) properties [130, 131] and the oral bio-availability [132]. QSAR methods have undergone rapid changes over the last years. The first 2D-QSAR models were based on descriptors derived from a two-dimensional graph representation of a molecule. These descriptors tried to characterize the most important molecular properties for the molecular interaction. However 2D-QSAR has important limitations for designing new molecules due to the lack of consideration of the 3D structure. 3D-QSAR emerged as an extension to the classical 2D-QSAR approach, which exploits the three-dimensional properties of the ligands to predict their biological activities [133]. The first QSAR model that integrated the 3D geometry to perform the predictions was the Comparative Molecular Field Analysis (CoMFA) [134]. In CoMFA, steric and electrostatic features of protein target are mapped onto a surface grid, which envelops a set of compounds superimposed in their active conformation. This grid acts as a surrogate of the binding site of the protein receptor and is frequently referred to as *pharmacophore*. However, this approach has an important limitation: a ligand molecule can only be represented by a single entity. Therefore, if a ligand binds with different conformations, only one of them can be represented in a 3D-QSAR model [133]. This limitation was overcome by 4D-QSAR methods, which include conformational flexibility and the freedom of alignment by ensemble averaging in the conventional three dimensional descriptors found in 3D-QSAR methods [135]. 4D-QSAR models have been successfully applied to simulate binding to cytochrome P450 3A4 [136], HIV-1 protease [137] or to the p38-mitogen-activated protein kinase (p38-MAPK) [138] among others [139]. More re-

cently, a 5D-QSAR model have been proposed [140]. This models includes a degree of freedom, the fifth dimension, that allows for a multiple representation of the atomic topology of the receptor surrogate (i.e. representation of different induced-fit models of the receptor). Finally, in the 6D-QSAR methods, a greater representation of the different solvation scenarios is included [141]. This allow for an even more realistic simulation of the binding process which ultimately is reflected in the development of better predictive models.

4. **Prediction and optimization of the ADMET properties.** Most of the drug discovery initiatives include a computational optimization of the compound’s PK properties. As previously mentioned, QSAR methods have been extensively applied to predict the PK properties of compounds 3. However, there are other *in-silico* approaches that play a substantial role in the ADMET prediction field. One of the tools that have significantly contributed to the field is the *Lipinski’s rule-of-five* , which aims to predict the odds of a compound to become a drug: *the compound drug-likeness* [142]. The Lipinski’s rule-of-five is a rule of thumb created by Christopher A. Lipinski based on the observation of chemical properties of drugs with favorable PK profile. It uses five arbitrary rules based of such number of chemical features to determine whether a compounds is likely to become a drug. If the compound fulfill (at least) four rules then it is considered as a drug-like candidate. However, assessment of compounds drug-likeness in absolute terms does not reflect adequately the whole range of compound qualities. To address this issue, a computational method that quantitatively measures the drug-likeness of a compound has been recently publshed [143]. Optimization in the ADMET properties of a compound is generally performed during the hit-to-lead and lead-optimization stages, concurrently with the optimization of the compound’s bio-activity. This multi-objective optimization process is brilliantly accomplished in the computational model developed by Besnard and

colleagues [144].

0.2 Drug discovery in Tuberculosis

About one-third of the world’s population is infected with *Mycobacterium tuberculosis* (MTB), the causative agent of tuberculosis (TB) [145]. Approximately 95% of infected individuals have latent MTB infections, which remain dormant until activated by specific environmental and host response events. Approximately 10% of latent infections eventually progress activating the disease. However, people with compromised immune systems, such as people with HIV, malnutrition or diabetes, or people who use tobacco, have a much higher risk of falling ill. Once the disease has been activated, when left untreated, kills more than half of the infected patients [146]. Despite of TB is considered as a treatable and curable disease, it remains as a top infectious disease killer worldwide. TB is usually treated with a standard 6 month course of combination of 4 antimicrobial drugs. Globally, the treatment success rate for people newly diagnosed with TB was 86% in 2013 [145]. Unfortunately, there is a increasing clinical occurrence of Multidrug-resistant tuberculosis (MDR-TB), which is a form of TB caused by bacteria that do not respond to first-line anti-TB drugs. In some cases, more severe drug resistance can develop such as the Extensively drug-resistant TB (XDR-TB), which is a form of MDR-tb tuberculosis that do no respond to any standard treatment, including the most effective second-line anti-TB drugs [147]. About 480,000 people developed MDR-TB in the world in 2014 while it is estimated that about 9.7% of MDR-TB cases had XDR-TB [145].

Infectious diseases in general, and TB in particular, are suffering from the lack of new innovative therapies [148]. The discovery and development of new antibiotics is widely recognized as one of the major global health emergencies. Most currently used antibiotics were discovered over the 1940s to 1960s [149]. Indeed, since 1987, no new class of antibiotics


has been discovered that is available for treatment of systemic bacterial infections [150]. Fortunately, a new class of antibiotics was recently discovered [151]. However, estimations say that it could take more than five years until it is available in the market. This lack of innovation has caused the re-emergence of diseases such as TB, dengue, and *African trypanosomiasis*. These diseases predominantly affect poor populations in less developed countries [148]. Concretely, the highest TB incidence rates are found predominantly in low-income countries including most countries in central and southern Africa, southern Asia and some countries from central America 9. The high incident rates of TB in developing countries reflects the urgent need for new and affordable medicines for the treatment of TB (among other infectious diseases). This need has not been directly reflected in traditional R&D programs of the pharmaceutical industry, mainly because they do not offer sufficient financial returns for the pharmaceutical industry to engage in research and development. This fact has led to the development of alternative mechanism to fight against TB and others infectious diseases:

1. Fostering research and development by philanthropic donations.

Charitable organizations, often private and corporate philanthropic foundations, donate money to drug research and development projects. In some cases, this money is assigned to public institutes to deeply investigate in the mechanism of bacterial infection and resistance. Such is the case of the \$20 million project given to the Broad Institute in the fight against Tuberculosis [152]. Other projects such as those funded by the Bill & Melinda Gates Foundation (www.gatesfoundation.org) seek for the development of less expensive and more effective diagnostic tools. These tools could reach higher TB target population and can be used at the point of care rather than requiring processing by a distant lab. Philanthropy is one of the major responsible of the important decrease in the TB mortality: the TB death rate dropped 47% between 1990 and 2015 [145].

2. **Nonprofit initiatives by Big Pharmaceutical companies.** Some pharmaceutical companies provide medicines and funds for medicines for developing countries or towards R&D for diseases that affect those countries. In some cases, the companies create specific institutes dedicated to the research and development of new medications against infectious diseases. Examples of this type of institutes include the Novartis Institute for Tropical Diseases (NITD) in Singapore, which focuses on dengue fever and TB, or the Tres Cantos Open Lab Foundation in Madrid, which is an independent, not-for-profit foundation established by GlaxoSmithKline in 2010 which is focused in TB, Malaria and Kinetoplastid infections. Unlike other type of projects, open-pharma initiatives have usually a very collaborative willingness, which many times results a with very fruitful partnerships between academia and the pharmaceutical institutes. An example of this type of collaborations is presented in chapter [REF PAPER TARGET].
3. **Public-private Partnerships (PPP).** The PPP Knowledge Lab (<https://pppknowledgelab.org/>) defines a PPP as a *long-term contract between a private party and a government entity, for providing a public asset or service, in which the private party bears significant risk and management responsibility, and remuneration is linked to performance*. Therefore, in a PPP, a private entity, which develops a public service, ultimately assumes a substantial financial, technical and operational risk in the project. The advantages of these type of approaches resides in their ability to bring the private sector expertise into the delivery of certain of some services traditionally developed by the public sector. Moreover, a PPP is structured in such way that the public entity does not incur any borrowing. Rather, the PPP borrowing is incurred by the private sector implementing the project. Interestingly, PPPs have been applied to cope with TB epidemic worldwide [153, 154]. Overall, in-deep analysis of the outcome produced by PPPs in TB, suggest that PPP could generally improve outcomes of a TB service. Specifically, the im-

provement is reflected throughout a earlier detection, better treatment administration, and broader service accessibility, especially in resource-limited areas [155]. The main beneficiary from this approach seems to be the final patient, who pays less for care while maintaining (or in some cases improving) the quality of treatment.



0.2.1 Research strategies against MTB.

Beyond the funding problems of research against MTB, there are numerous technical challenges in identifying new antitubercular compounds [156]. One of the main difficulties is the extremely slow growth rate of *Mycobacterium tuberculosis* as this is ultimately reflected in the rate of progress of discovery research. Another aspect is associated with the nature of the bacteria; MTB is a respiratory pathogen, and therefore has to be handled under strict safety conditions (Bio-safety Level 3) requiring expensive specialist facilities. MTB have a very unusual cell wall that impedes many compounds from penetrating into the cell [157]. Additionally, this bacteria has efflux pumps that transport compounds out of the cell and that have been implicated in resistance to antibiotics [158]. Another problem, consequence of the long-term therapy required to treat TB, is that anti-tubercular drugs need to be safe for periods over 6 months (or even more when dealing with MDR-TB or XDR-TB), without significant side effects or drug-drug interactions. [AQUI]

The search for new anti-tubercular is therefore a challenging task. Currently, researchers are employing many different approaches in parallel including HTS and computational methods. Such screenings aim to find new molecular entities that could lead to the development of new antibacterial treatments. One of these HTS approaches is the *cell based phenotypic screening*, which represents a powerful approach to identify antibacterial compounds and elucidate novel targets [159]. Some phenotypic screenings are combined with toxicity assays to find those compounds with high anti-tubercular activity and good PK profile [160]. Other HTS approaches aim to identify highly potent molecules against an essential MTB target [161, 162]. Computational methods are essential in the analysis of the vast amount of data generated by HTS and provide a very powerful tool to identify those candidate molecules that could be prioritized for further development.

In-silico approaches in TB

Similarly to many other diseases, CADD methods play a substantial role in the Tuberculosis R&D field. Uncountable *in-silico* methods have been published over the last decade [163], each of them applying different strategies to solve a specific bio-medical question. However, all of them pursue the very same goal: fueling drug discovery against TB. Table 2 contains some remarkable *in-silico* resources for the fight against TB. The purpose of these resources is very diverse. One popular resource is targetTB, which consist on an open-source pipeline to identify targets in MTB [124]. Similarly, chapter [REF OUT CHAPTER] presents how the combination of three orthogonal approaches can help to identify the molecular targets of novel anti-tubercular compounds. Other resources, such as TDRtargets [164] (<http://tdrtargets.org/>) and CCD-TB [165], blend a target detection tool with a publicly accesible database of known existing targets and anti-microbial compounds. Some methods, on the other hand, are focused on provide specific insights into a specific problem in TB treatment. Such is the case of the computational detection of Comtan as a potential agent in the treatment of MDR-TB and XDR-TB [166], or the examples from [167] and [168]. Most of these resources take advantage of Tuberculist [169], a database of experimentally measured gene essentiality in MTB; and TuberQ [170], which contains information about MTB protein druggability. Is such the importance of computational resources in TB research that recently a Mobile app, called TB-Mobile [163, 171], was published. TB-Mobile provides an agile way to interact with TB data and includes some chemoinformatics tools for clustering and finding new molecular targets to known anti-tubercular compounds. This app is therefore pushing the boundaries of real science on mobile devices in several important ways, and could set up a milestone in bringing mobile apps into the computational biology research field.

Overall, *in-silico* methods have played a major role in the research against tropical infectious diseases. Particularly, Tuberculosis have benefited enormously from the contribution of such methods and therefore

they are partly responsible of the improvement in the outcome of the disease.

Type of method	Name	Resource description	Reference(s)
Target identification pipeline	TargetTB	Target prioritization in TB thorough a computational pipeline	[124]
Database	TDRtargets	Database and method for identification of potential MTB targets	[164]
Application of bioinformatics tools	-	Drug repositioning applied to MDR-TB and XDR-TB	[166]
Database	CDD-TB	Database of anti-tubercular compounds reported from HTS alongside computational models to analyze the data	[165]
Application of bioinformatics and chemoinformatics tools	-	Identification of the MTB targets of bioactive anti-tubercular compounds using three orthogonal <i>in-silico</i> approaches	[128, 172]
Application of bioinformatics tools	-	Homology modelling and virtual doking applied to ligand-protein interaction prediction	[167]

Application of chemoinformatics tools	TB Mobile	Mobile app that provides a platform to interact with data collected from CDD-TB	[163, 171]
Application of bioinformatics and chemoinformatics tools	-	Identification of Enoyl acyl carrier protein reductase binders using a 3D-QSAR approach	[168]
Application of bioinformatics tools	-	Interactome computational analysis to identify potential mechanisms of drug resistance to TB therapies	[124]
Database	Tuberculist	Database of experimentally measured gene essentiality	[169]
Database	TuberQ	MTB protein druggability database	[170]

Table 2: Table containing multiple computational resources used in the discovery and research against TB

0.3 Targeted cancer therapies

Cancer is one the leading causes of morbidity and mortality worldwide. In 2012 there were more than 14 million new cases and 8.2 million cancer

related deaths. Moreover, the cancer global burden is expected to rise by about 70% over the next 20 years [173]. Intravenous cytotoxic chemotherapy has traditionally prevailed as the main therapeutic choice in cancer treatment. Chemotherapy drugs target rapidly dividing cells, including cancer cells and certain normal tissues. Hence, the lack of specificity of the chemotherapy treatment leads to strong side effects such as hair loss, gastrointestinal symptoms, fatigue or myelosuppression, among others. In the past decade, however, the arrival of targeted cancer therapies have dramatically transformed cancer treatment. Targeted cancer therapies are drugs designed to specifically interfere with molecules necessary for tumorigenesis. The higher specificity associated to these drugs makes them a more powerful and less harming alternative for cancer treatment. Although chemotherapy remains the treatment of choice for many malignancies, targeted therapies are now an essential component of treatment for many types of cancer, including breast, colorectal, non-small cell lung cancer (NSCLC), as well as lymphoma, several classes of leukemia, and multiple myeloma. There are two main types of targeted cancer therapies: monoclonal antibodies and small molecule inhibitors.

0.3.1 Monoclonal antibodies

Monoclonal antibody-based therapy for cancer has become established over the past 15 years. Additionally, it is currently one of the most successful and promising approaches for treating cancer patients. Monoclonal antibodies are target specific, which means that they exclusively target only one protein. Moreover, their protein target has to be extracellular, as the antibodies cannot enter the cell through the plasma membrane. Monoclonal antibodies can kill tumour cells throughout multiple mechanisms of action [174]. One of the classic mechanisms consist on direct action of the antibody on the target protein. An example of this class is the monoclonal antibody cetuximab, an epidermal growth factor receptor (EGFR) inhibitor used in EGFR-positive colorectal can-

cer [175] and squamous cell carcinoma of the head and neck (SCCHN) [176]. Another mechanism consist on the activation of the immune system response to kill cancer cells. Immunotherapies are becoming increasingly popular and its currently one of the most promising fields of cancer research. Examples of this class include the immune checkpoint inhibitors pembrolizumab (PD-1), atezolizumab (PDL-1) and ipilimumab (CTLA-4) [177]; or the CD52 antibody alemtuzumab [178]. Tumour vascularization and stroma have also been targeted by antibody-based therapies. For example, bevacizumab, is a monoclonal antibody that blocks angiogenesis by targeting the vascular endothelial growth factor receptor (VEGFR) [179]. It is currently used as a single agent or in combination with chemotherapy to treat certain types of advanced cancer, including colorectal, NSCLC, glioblastoma or kidney cancer [180]. Finally, several conjugated antibodies have been approved to treat cancer. An example of this class is ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20, for patients with relapsed B-cell non-Hodgkin’s lymphomas. This drug combines the monoclonal antibody ibritumomab in conjunction with the chelator tiuxetan, to which radioactive isotope is added [181]. Undoubtedly, antibody-based cancer therapies have significantly contributed to the improvement of cancer survival. However, these therapies have still important limitations which prevents them for broader application. One the major limitations is the temporally efficacy of some treatments. Patients with malignant tumours may not achieve a long-term therapeutic effect consequence of the multiple tumour escape mechanisms [174]. Deeper understanding of the tumor biology may provide insight into selection of patients who are suited to a specific antibody treatment. In summary, monoclonal antibodies has shown a great potential in the treatment of cancer. However, there are important limitations that need to be addressed in order to increase the clinical impact of this type of treatment.

0.3.2 Small molecule kinase inhibitors

Small molecule inhibitors is the second main class of targeted cancer therapies. Unlike monoclonal antibodies, they can penetrate into the cell throughout the plasma membrane. Small molecule targeted cancer therapies focus on inhibiting protein kinases. In fact, kinases have been established as promising drug targets for the treatment of various types of human disease because of their essential roles in signal transductions and regulation of a range of cellular activities. However, the vast majority of these targets are being investigated for the treatment of cancer [182]. Over the last years, many kinases have been found to be deeply involved in the processes leading to tumorigenesis. Depending of their role in cancer progression we can classify small molecule kinase targets into different groups. First, there are kinases that have become insensitive to normal regulatory mechanisms. The altered activity of such kinases can be the consequence of genetic alterations (e.g. mutations or translocations) or epigenetic changes (e.g. gene amplification, increased expression) and are considered to be oncogenic. The constitutive activity of this class of kinase target makes them essential for survival and/or proliferation of the cancer cell. This phenomenon is known as oncogene addiction [183], and makes the cancer cell exceptionally susceptible to the oncogene kinase inhibitor. One of best examples of this phenomenon is the activating V600E BRAF mutation. About 50 % of melanomas harbour this oncogenic mutation [184]. Currently, there are two small molecules FDA approved inhibitors (vemurafenib [185] and dabrafenib [186]) that specifically target the BRAF V600E-mutated metastatic melanoma. Inhibiting mutationally activated kinases (i.e., oncogenic kinases) has resulted in the most dramatic clinical responses [182]. A second class of target kinases is composed by those non-oncogenic kinases whose presence is preferentially required for the survival and/or proliferation of tumour cells. These kinases are usually located in key signalling pathways downstream of cancer oncogenes. Examples of this type of targets include MEK1 and MEK2 (also known as MAP2K1 and MAP2K2), which are targeted by several small molecule inhibitors such as trametinib or cobimetinib. Combina-

tions of these inhibitors with oncogene inhibitors led into a significant improvement in patient survival compared with single treatment regime in melanoma [187, 188]. Another class of kinases targets are those highly expressed in the tumour stroma and that are required for different stages of tumour formation and development in the human host. Examples of this class include the inhibition of VEGFR by pazopanib or other small molecule inhibitors [189]. Kinase targets of the second and third classes are not directly oncogenic, but instead are required for the survival and proliferation of cancer cells. Hence, the inhibition of these kinases is usually combined with oncogene inhibition to strengthen the inhibitory effect and overcome resistance due to activation of downstream survival mechanisms [190].

Protein kinases are defined by their ability to catalyse the transfer of the terminal phosphate of ATP to a substrate that usually contains a serine, threonine or tyrosine. They share a highly conserved arrangement of secondary structure elements that fold into a bi-lobed catalytic core structure (N-terminal lobe and C-terminal lobe), with ATP binding site located in a deep cleft located between the two lobes [191] 10. The ATP adenine ring forms hydrogen bonds with the kinase hinge region (i.e., the segment that connects the amino and carboxy terminal kinase domains), while the ribose and triphosphate groups of ATP bind in a hydrophilic channel adjacent to the ATP binding site that contains conserved residues that are essential to catalysis. Additionally, kinases have a conserved activation loop, which regulates the kinase activity and that contains a extremely conserved DFG motif (i.e., aspartic acid, phenylalanine and glycine) at the start of the loop. The structural disposition of the activation loop switches between the active and inactive conformations of the protein kinase [191]. Since the catalytic mechanism requires the exact positioning of highly conserved active site residues, the kinase active state is rigid and highly conserved. In contrast, kinase inactive states are structurally highly diverse and dynamic [192]. Furthermore, the kinase ATP binding site contains a highly flexible phosphate-binding loop (P-loop). In many kinases the the P-loop contains an aromatic residue that points upward

in the active kinase state, enabling the binding of ATP. Finally, kinases contain a key residue in the ATP-binding site known as *gatekeeper*. This residue is located close to the hinge region and controls the access of small molecule inhibitors to a hydrophobic pocket in the active site that is not contacted by ATP [193] 10.




Figure 10: 3D structure of ABL1 kinase in complex with imatinib displaying the different structural regions of protein kinases. The structure represents the typical kinase inactive DGF-out conformation. The protein is represented as ribbons and the ligand as sticks. The activation loop is coloured in cyan, the DGF motif in blue, the P-loop is coloured in red, the hinge region in purple and the α C helix in green. PDB accession code 2HYY.

Most of the current small molecule kinase inhibitors are ATP-competitive that mimics the ATP binding mode. However, depending of their specific binding mode small molecule protein kinase inhibitors can be classified into multiple classes:

1. **Type I inhibitors.** This type of ATP-competitive inhibitor bind the active conformation of the protein kinase. As mentioned above, the kinase active state is well defined and it is more rigid than inactive kinase states. Moreover, is very conserved among kinases making the development of selective type I inhibitors a very challenging task. The specificity is therefore given by unusual active site features such as rare amino acids in conserved positions, inserts/deletions, and, in some cases, residues that can be targeted by irreversible inhibitors. Additionally, small gatekeeper residues, such as threonine, can provide access to a hydrophobic *back pocket* not contacted by ATP [194]. Type 1 inhibitors typically consist of a heterocyclic core scaffold that occupies the adenine binding site alongside side chains that occupy the adjacent hydrophobic regions 11. Examples of this class include the EGFR inhibitors gefitinib and erlotinib, the BRAF V600E-mutant inhibitor vemurafenib, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib or the Bcr-Abl tyrosine kinase inhibitor dasatinib. The complete list of type I inhibitors is shown in table 3.

2. **Type II inhibitors.** Type 2 kinase inhibitors recognize the inactive conformation of the kinase. The most frequent conformation recognized by type 2 inhibitors is the so-called DFG-out. This conformation is created by a rearrangement of the activation loop that creates an extended and flexible binding pocket adjacent to the ATP binding site 11. The high degree of flexibility generated by this conformation suggests that inhibitors targeting such states should have a better chance being selective. However, recent comprehensive analysis of type II selectivity revealed that many kinases can assume this inactive state and that type II inhibitors may not be intrinsically more selective than type I inhibitors [195]. The original discovery that inhibitors such as imatinib and sorafenib bind in the type 2 conformation was serendipitous, but subsequent analysis of multiple type 2 kinase inhibitor revealed that most of them share a similar binding pattern [195]. Other examples of type II kinase in-

hibitors include the Bcr-Abl tyrosine kinase inhibitors nilotinib or ponatinib. The complete list of type II inhibitors is shown in table 3.

3. **Targeting P-loop conformations.** In kinase-inhibitor complexes, the P-loop may fold into the ATP -binding site, forming aromatic stacking interactions with the inhibitor [196]. An additional characteristic of folded P-loop conformations is the induction of a large binding cavity between the P-loop and the α C helix 11. This binding cavity is present in many structures with folded P-loops and has been explored, for the first time, by the selective ERK1/2 inhibitor SCH772984 [197]. Multiple kinases can adopt a folded P-loop conformation, and the unique geometric features of this binding mode, may lead into the development of selective inhibitors for these kinases. Nevertheless, none of FDA approved drugs adopt this conformation, and therefore a broader general demonstration of this inhibitor binding mode is still necessary.
4. **Type III allosteric inhibitors.** Type III kinase inhibitors are non ATP-competitive inhibitors that bind the kinase in a allosteric site (i.e., a site distinct from the enzyme active site that can bind a ligand) modulating kinase activity in an allosteric manner. Allosteric inhibitors tend to exhibit the highest degree of selectivity since they exploit binding sites and regulatory mechanisms that are unique to each particular kinase 11. Most allosteric kinase inhibitors have been discovered serendipitously, and currently there is no general strategy for identifying such compounds. The best examples of this class are the MEK1/MEK2 allosteric inhibitors trametinib and cobimetinib, which occupy a pocket adjacent to the ATP binding site. Other FDA approved non-ATP competitive inhibitors are shown in table 3.
5. **Covalent inhibitors.** The last class of kinase inhibitors are those capable of forming an irreversible, covalent bond to the kinase active site, most frequently thorough the reaction with a nucleophilic

cysteine residue [198]. Most of the covalent kinase inhibitors have been developed by structure-guided incorporation of an electrophilic group into an inhibitor that already had sub-micromolar binding affinity [199]. Although a large number of kinases have cysteine residues in and around the ATP-binding site, there are not conserved cysteines residues across the human kinome [200]. This lack of conservation has been used to develop selective irreversible inhibitors of kinases harbouring cysteine residues in the ATP-binding site. However, cross-reactivity of cysteine-reactive groups can lead to non-selective reactions with off-target proteins, which eventually gives rise to increased toxicity and lack of target specificity [201, 202]. Examples of FDA approved irreversible inhibitors include the Bruton’s tyrosine kinase (BTK) Ibrutinib or the EGFR inhibitor afatinib.




Figure 11: Structural features of the canonical classes of small molecule kinase inhibitors. The center panel shows the main interaction sites of different inhibitors types. The side panels show the specific structural features of each of the binding modes. Figure extracted from [192].

Compound name	Pharmacological Target	Binding mode	First FDA approval
Imatinib	ABL1	Type II	2001
Gefitinib	EGFR	Type I	2003
Erlotinib	EGFR	Type I	2005
Sorafenib	VEGFR, PDGFR, BRAF, etc.	Type II	2005
Dasatinib	ABL1	Type I	2006
Sunitinib	VEGFR	Type I	2006
Nilotinib	ABL1	Type II	2007
Lapatinib	EGFR, HER2	Type I and II	2007
Pazopanib	VEGFR, PDGFR, c-KIT, etc.	Type I and II	2009
Crizotinib	ALK, ROS1	Type I	2011
Vemurafenib	BRAF	Type I	2011
Ruxolitinib	JAK1/2	Type I	2011
Vandetanib	VEGFR	Type I	2011
Bosutinib	BCR-ABL1	Type I	2012
Tofacitinib	JAK3	Type I	2012
Axitinib	VEGFR, PDGFR, c-KIT	Type I	2012
Cabozantinib	c-MET	Type II	2012
Regorafenib	VEGFR, PDGFR, etc.	Type II	2012
Ponatinib	ABL1	Type II	2012
Dabrafenib	BRAF	Type I	2013
Trametinib	MEK1/2	Type III	2013
Afatinib	EGFR	Type I, Irreversible	2013
Ibrutinib	BTK	Type I, Irreversible	2013
Idelalisib	PI3K-delta	Type I	2014
Nintedanib	VEGFR, PDGFR, etc.	Type II	2014
Ceritinib	ALK, MET	Type II	2014
Lenvatinib	VEGFR, PDGFR, c-KIT, FGFR, etc.	Type V [†]	2015
Palbociclib	CDK4/6	Type I	2015

[†] In a recent publication, lenvatinib was proposed as a special class of kinase inhibitors (the so-called type V inhibitors). Compounds of this class are those binding both the ATP-binding site and the neighboring allosteric region in kinases with DFG-in conformation [203].

Table 3: FDA approved kinase inhibitors alongside their pharmacological target, binding mode and year of FDA approval.

The approval of imatinib in 2001 radically transformed the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Since then, more than 27 different small molecule kinase inhibitors have been approved by the FDA 3, and many others are currently

in clinical trials for the treatment of cancer. Despite of their great success in cancer treatment, small molecule kinase inhibitors suffer from major limitations that need to be addressed to improve their clinical impact. Next, I outline some of their most important challenges and limitations:

1. Of the total 538 estimated human kinases [191], only a few, and most of them belonging to the tyrosine kinase group, have been pharmacologically targeted by small molecule inhibitors. It is thus necessary to increase the spectrum of clinically targeted kinases. Moreover, the increment of the number of targeted kinases would create new therapeutic opportunities for disorders where kinases play an important, but yet clinically unexplored role.
2. Other important limitation is the lack of specificity of many small molecule kinase inhibitors. This is mainly consequence of the high structural conservation of the ATP-binding site in kinases, which causes that a large number of inhibitors interact with more than one target [204]. The multitarget nature of many kinase inhibitors gives rises to severe side effects that dramatically restricts its applicability to the clinic. Fostering the development of type III allosteric inhibitors would lead into more selective inhibitors preventing the appearance of unexpected toxicities.
3. Related to the previous point, the mechanistic basis of unexpected toxicities observed during the preclinical and clinical stages need to be studied more rigorously. Improved documentation of kinase inhibitor specificity and observed toxicities would provide a valuable database for understanding whether there are particular kinases of which inhibition should be particularly avoided [205].
4. The most important limitation of small-molecule kinase inhibitors, in particular, and targeted cancer therapies, in general, is the rapid acquisition of drug resistance. The duration of clinical benefits is frequently short lived, which dramatically restricts the utility of many targeted cancer therapies. The next section will focus on the

mechanistic basis of resistance to targeted cancer therapies, with particular emphasis on mutations of kinase targets altering the efficacy of the treatment.

0.3.3 Resistance to targeted cancer therapies

Drug resistance is a major problem in the clinic. Resistance to both chemotherapy agents and targeted cancer therapies is hampering the success of many anti cancer treatments. The advent of new high throughput genomic technologies in combination with bioinformatics and systems biology approaches have enhanced the understanding of the molecular events underpinning treatment failure. However, we are still far from overcoming the emergence of drug resistance in cancer targeted therapies. One of the reasons leading to the complex drug resistance problem is the considerable amount of molecular mechanism leading to drug resistance [190]. Some mechanisms of resistance for specific molecular targets share many features with the classic cytotoxic chemotherapy, while others are genuine to the targeted cancer therapies. One of the classic mechanisms of resistance is caused by the pharmacokinetics properties (ADME) of the drugs, which added to the limited amount of drug that can be systemically administered confine the amount of drug that reaches the tumour. That means that the concentration of drug that eventually reaches the cancer cells is lower than the one required to perform the desired antiproliferative activity ?? . At the level of the tumour, various resistance mechanisms can operate, such as activation of survival signalling pathways and the inactivation of downstream death signalling pathways [206], oncogenic bypass and pathway redundancy [207], factors associated to the tumour microenviroment [208] or epigenetic alterations [209].

Importantly, alterations in the drug target one of the most frequent mechanism of resistance in targeted cancer therapies. Increased expression of the molecular target reduces the effectiveness of inhibitors of these targets because more target molecules be must be inhibited to have a ef-

fective therapeutic effect. For instance, the androgen receptor (AR) is genomically amplified in approximately 30% of prostate cancers with acquired resistance to standard androgen deprivation therapy. In such cases, treatment using testosterone lowering drugs such as leuprolide and AR antagonists such as bicalutamide is not effective and alternative treatments are thus necessary [210].

Most of the small molecule targeted cancer therapies target oncogenic kinases that are responsible of the tumour proliferation and/or development 0.3.2. Mutations of these oncogenic kinases can alter the binding of the small molecule kinase inhibitor giving rise to a reestablishment of the tumour proliferation activity. Moreover, evidence continues to emerge that cancers are characterized by extensive intratumour genetic heterogeneity (ITH), and that patients being considered for treatment with a targeted agent might, therefore, already possess resistance to the drug in a small population of cells [211]. This mechanism of resistance has been extensively reported over the last years [212, 213]. The first mutation identified in patients with CML who relapsed on treatment with imatinib was in the gatekeeper residue of BCR-ABL1, T315. This missense mutation hinders imatinib binding while preserving the catalytic activity that is needed for the oncogenic function of BCR-ABL1 [214]. Since then, more than BCR-ABL1 100 different mutations have been reported [215]. Second-generation BCR-ABL1 inhibitors (e.g., nilotinib, dasatinib and bosutinib) were developed for the treatment of patients with acquired resistance to imatinib. However, the BCR-ABL1 T315I gatekeeper mutation confers resistance to all currently approved ABL1 TKIs other than the newest of these molecules, ponatinib [215]. Similarly to the BCR-ABL1 case, acquired resistance to EGFR inhibitors such as gefitinib or erlotinib is common 0.3.2. Studies showed that more than 50% of the EGFR-gefitinib resistant cases harbored a secondary EGFR-T790M mutation [216]. Such is the impact of this mutation for the treatment of NSCLCs, that a third new generation of EGFR-T790M selective inhibitors have been designed to overcome resistance to EGFR-T790M positive patients [217, 218]. However, recent studies showed that third generation irre-

versible EGFR inhibitors also experience the emergence of resistance mutations [219]. Crizotinib is a small molecule kinase inhibitor approved for the treatment of some types of NSCLC. It performs its pharmacological activity by targeting the ALK and ROS-1 kinases 0.3.2. Some studies in small cohorts of patients have already shown that mutations ALK kinase domain such as G1269A, L1198F, L1196M can drive acquired resistance to crizotinib [220, 221]. The mutations described to date span the entire ALK kinase domain and may also confer variable degrees of resistance to second-generation ALK inhibitors [222].

The ABL1-imatinib, EGFR-gefitinib and ALK-crizotinib cases are the probably the best studied examples. However, many other kinase mutations have been reported as responsible of resistance to small molecule targeted cancer therapies. [AQUI] Future improvement in the sensitivity of genomic high throughput technologies will, most likely, increase the number of these mutants [211]. . Hence, there is a need to rationally use bla bla. . Early detection of pre-existing or emerging drug resistance could enable more personalized use of targeted cancer therapy, as patients could be stratified to receive the therapies that are most likely to be effective. We consider how monitoring of drug resistance could be incorporated into clinical practice to optimize the use of targeted therapies in individual patients. Combinations of drugs, Personalized, early detection, computational method introduce our chapter. Schmitt,

Bibliography

- [1] A Kessel and N Ben-Tal. *Introduction to Proteins: Structure, Function, and Motion*. Chapman & Hall/CRC Mathematical and Computational Biology. CRC Press, 2010. ISBN: 9781439810729 (cit. on p. 2).
- [2] B. Alberts. *Molecular Biology of the Cell: Reference edition*. Molecular Biology of the Cell: Reference Edition v. 1. Garland Science, 2008. ISBN: 9780815341116 (cit. on p. 2).
- [3] Wolfgang Kabsch and Christian Sander. “Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features”. In: *Biopolymers* 22.12 (1983), pp. 2577–2637. ISSN: 1097-0282. DOI: 10 . 1002 / bip . 360221211 (cit. on p. 3).
- [4] K A Dill. “Dominant forces in protein folding.” In: *Biochemistry* 29.31 (1990), pp. 7133–7155. ISSN: 0006-2960. DOI: 10 . 1021 / bi00483a001 (cit. on p. 3).
- [5] Cyrus Chothial and Arthur M Lesk. “proteins”. In: 5.4 (1986), pp. 823–826 (cit. on pp. 4, 5).
- [6] Buyong Ma et al. “Protein – protein interactions : Structurally conserved residues distinguish between binding sites and exposed protein surfaces”. In: Track II (2003) (cit. on p. 4).

- [7] Rajkumar Sasidharan and Cyrus Chothia. “The selection of acceptable protein mutations”. In: 2007 (2007) (cit. on p. 4).
- [8] Annabel E Todd, Christine A Orengo, and Janet M Thornton. “Evolution of Function in Protein Superfamilies , from a Structural Perspective”. In: (2001). DOI: 10 . 1006 / jmbi . 2001 . 4513 (cit. on p. 4).
- [9] J C KENDREW et al. “Structure of Myoglobin: A Three-Dimensional Fourier Synthesis at 2 [angst]. Resolution”. In: *Nature* 185.4711 (Feb. 1960), pp. 422–427 (cit. on p. 5).
- [10] Helen M Berman et al. “The Protein Data Bank”. In: *Nucleic Acids Research* 28.1 (Jan. 2000), pp. 235–242. DOI: 10 . 1093 / nar / 28 . 1 . 235 (cit. on p. 5).
- [11] John C Norvell and Jeremy M Berg. “Update on the Protein Structure Initiative”. In: *Structure* 15.12 (Dec. 2007), pp. 1519–1522. ISSN: 0969-2126. DOI: <http://dx.doi.org/10.1016/j.str.2007.11.004> (cit. on pp. 5, 13, 15).
- [12] Opher Gileadi et al. “The scientific impact of the Structural Genomics Consortium : a protein family and ligand-centered approach to medically-relevant human proteins”. In: (2007), pp. 107–119. DOI: 10 . 1007 / s10969-007-9027-2 (cit. on p. 5).
- [13] M S Smyth and J H J Martin. “x Ray crystallography”. In: *Molecular Pathology* 53.1 (Feb. 2000), pp. 8–14. DOI: 10 . 1136 / mp . 53 . 1 . 8 (cit. on p. 6).
- [14] Roslyn M Bill et al. “perspective Overcoming barriers to membrane protein structure determination”. In: *Nature Biotechnology* 29.4 (2011), pp. 335–340. ISSN: 1087-0156. DOI: 10 . 1038 / nbt . 1833 (cit. on p. 7).
- [15] Michael B Yaffe. “X-ray crystallography and structural biology”. In: *Critical Care Medicine* 33.12 (2005). ISSN: 0090-3493 (cit. on p. 7).

- [16] A L Morris et al. “Stereochemical quality of protein structure coordinates.” In: *Proteins* 12.4 (Apr. 1992), pp. 345–64. ISSN: 0887-3585. DOI: 10.1002/prot.340120407 (cit. on p. 7).
- [17] Gerhard Wider. “Structure Determination of Biological Macromolecules in Solution Using NMR spectroscopy”. In: 1294 (2000), pp. 1278–1294 (cit. on pp. 7, 8).
- [18] David G Gadian et al. “Mechanisms of Secondary Brain Damage: Current State”. In: ed. by Alexander Baethmann, Oliver Kempfski, and Ludwig Schürer. Vienna: Springer Vienna, 1993. Chap. NMR Spectr, pp. 1–8. ISBN: 978-3-7091-9266-5. DOI: 10.1007/978-3-7091-9266-5_1 (cit. on p. 8).
- [19] Kicking Up et al. “THE REVOLUTION WILL NOT BE CRYSTALLIZED”. In: (2015), pp. 7–9 (cit. on p. 8).
- [20] Heena Khatter et al. “Structure of the human 80S ribosome”. In: *Nature* 520.7549 (Apr. 2015), pp. 640–645. ISSN: 0028-0836 (cit. on p. 9).
- [21] Jianhua Zhao, Samir Benlekbir, and John L Rubinstein. “Electron cryomicroscopy observation of rotational states in a eukaryotic V-ATPase”. In: *Nature* 521.7551 (May 2015), pp. 241–245. ISSN: 0028-0836 (cit. on p. 9).
- [22] Maofu Liao et al. “Structure of the TRPV1 ion channel determined by electron cryo-microscopy”. In: *Nature* 504.7478 (Dec. 2013), pp. 107–112. ISSN: 0028-0836 (cit. on p. 9).
- [23] Xiao-chen Bai et al. “An atomic structure of human [ggr]-secretase”. In: *Nature* 525.7568 (Sept. 2015), pp. 212–217. ISSN: 0028-0836 (cit. on p. 9).
- [24] D T Jones, W R Taylort, and J M Thornton. “A new approach to protein fold recognition”. In: *Nature* 358.6381 (July 1992), pp. 86–89 (cit. on p. 11).
- [25] J U Bowie, R Luthy, and D Eisenberg. “A method to identify protein sequences that fold into a known three-dimensional structure”. In: *Science* 253.5016 (July 1991), pp. 164–170 (cit. on p. 11).

- [26] Jooyoung Lee, Sitao Wu, and Yang Zhang. “From Protein Structure to Function with Bioinformatics”. In: ed. by Daniel John Rigden. Dordrecht: Springer Netherlands, 2009. Chap. Ab Initio, pp. 3–25. ISBN: 978-1-4020-9058-5. DOI: 10.1007/978-1-4020-9058-5_1 (cit. on p. 11).
- [27] Daniel Russel et al. “Putting the Pieces Together: Integrative Modeling Platform Software for Structure Determination of Macromolecular Assemblies”. In: *PLoS Biology* 10.1 (Jan. 2012), e1001244. ISSN: 1544-9173. DOI: 10.1371/journal.pbio.1001244 (cit. on p. 11).
- [28] Narayanan Eswar et al. “Comparative protein structure modeling using MODELLER.” en. In: *Current protocols in protein science / editorial board, John E. Coligan ... [et al.]* Chapter 2 (Dec. 2007), Unit 2.9. ISSN: 1934-3663. DOI: 10.1002/0471140864.ps0209s50 (cit. on pp. 12, 17).
- [29] D Baker. “Protein structure prediction and structural genomics”. In: *Science* 294 (2001), pp. 93–96. ISSN: 00368075. DOI: 10.1126/science.1065659 (cit. on p. 13).
- [30] Su Yun Chung and S Subbiah. “A structural explanation for the twilight zone of protein sequence homology”. In: *Structure* 4.10 (Oct. 1996), pp. 1123–1127. ISSN: 09692126. DOI: 10.1016/S0969-2126(96)00119-0 (cit. on p. 13).
- [31] C Sander and R Schneider. “Database of homology-derived protein structures and the structural meaning of sequence alignment.” In: *Proteins* 9.1 (Jan. 1991), pp. 56–68. ISSN: 0887-3585. DOI: 10.1002/prot.340090107 (cit. on pp. 13, 16).
- [32] Evandro Ferrada and Francisco Melo. “Nonbonded terms extrapolated from nonlocal knowledge-based energy functions improve error detection in near-native protein structure models”. In: *Protein Science* 16.7 (2007), pp. 1410–1421. ISSN: 1469-896X. DOI: 10.1110/ps.062735907 (cit. on p. 14).

- [33] A Fiser, R K Do, and A Sali. “Modeling of loops in protein structures.” In: *Protein science : a publication of the Protein Society* 9.9 (Sept. 2000), pp. 1753–73. ISSN: 0961-8368. DOI: 10 . 1110/ps.9.9.1753 (cit. on p. 14).
- [34] A Kidera. “Enhanced conformational sampling in Monte Carlo simulations of proteins: application to a constrained peptide.” In: *Proceedings of the National Academy of Sciences of the United States of America* 92.21 (Oct. 1995), pp. 9886–9889. ISSN: 0027-8424 (cit. on p. 14).
- [35] D.B. McGarrah and R.S. Judson. “Analysis of the genetic algorithm method of molecular conformation determination”. In: *Journal of Computational Chemistry* 14.11 (Nov. 1993), pp. 1385–1395. ISSN: 0192-8651. DOI: 10 . 1002/jcc.540141115 (cit. on p. 14).
- [36] Domenico Cozzetto et al. “Assessment of predictions in the model quality assessment category”. In: *Proteins: Structure, Function, and Bioinformatics* 69.S8 (2007), pp. 175–183. ISSN: 1097-0134. DOI: 10 . 1002/prot.21669 (cit. on p. 14).
- [37] Francisco Melo, Roberto Sánchez, and Andrej Sali. “Statistical potentials for fold assessment.” In: *Protein science : a publication of the Protein Society* 11.2 (Mar. 2002), pp. 430–48. ISSN: 0961-8368. DOI: 10 . 1002/pro.110430 (cit. on p. 14).
- [38] R Samudrala and J Moult. “An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction.” In: *Journal of molecular biology* 275.5 (Feb. 1998), pp. 895–916. ISSN: 0022-2836. DOI: 10 . 1006/jmbi.1997.1479 (cit. on p. 15).
- [39] DAVID A CASE et al. “The Amber Biomolecular Simulation Programs”. In: *Journal of computational chemistry* 26.16 (Dec. 2005), pp. 1668–1688. ISSN: 0192-8651. DOI: 10 . 1002/jcc.20290 (cit. on p. 15).

- [40] Bernard R. Brooks et al. “CHARMM: A program for macromolecular energy, minimization, and dynamics calculations”. In: *Journal of Computational Chemistry* 4.2 (1983), pp. 187–217. ISSN: 0192-8651. DOI: 10.1002/jcc.540040211 (cit. on p. 15).
- [41] Federico Fogolari, Alessandro Brigo, and Henriette Molinari. “Protocol for MM/PBSA molecular dynamics simulations of proteins.” In: *Biophysical journal* 85.1 (July 2003), pp. 159–66. ISSN: 0006-3495. DOI: 10.1016/S0006-3495(03)74462-2 (cit. on p. 15).
- [42] P D Thomas and K A Dill. “Statistical potentials extracted from protein structures: how accurate are they?” In: *Journal of molecular biology* 257.2 (Mar. 1996), pp. 457–69. ISSN: 0022-2836. DOI: 10.1006/jmbi.1996.0175 (cit. on p. 15).
- [43] Min-yi Shen and Andrej Sali. “Statistical potential for assessment and prediction of protein structures”. In: *Protein Science : A Publication of the Protein Society* 15.11 (Nov. 2006), pp. 2507–2524. ISSN: 0961-8368. DOI: 10.1110/ps.062416606 (cit. on p. 15).
- [44] Hongyi Zhou and Yaoqi Zhou. “Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction.” In: *Protein science : a publication of the Protein Society* 11.11 (Dec. 2002), pp. 2714–26. ISSN: 0961-8368. DOI: 10.1110/ps.0217002 (cit. on p. 15).
- [45] Manfred J Sippl. “Knowledge-based potentials for proteins”. In: *Current Opinion in Structural Biology* 5.2 (Apr. 1995), pp. 229–235. ISSN: 0959440X. DOI: 10.1016/0959-440X(95)80081-6 (cit. on p. 15).
- [46] Changsheng Du and Xin Xie. “G protein-coupled receptors as therapeutic targets for multiple sclerosis”. In: *Cell Res* 22.7 (June 2012), pp. 1108–1128. ISSN: 1001-0602 (cit. on p. 15).

- [47] Kim R Kampen. “Membrane Proteins: The Key Players of a Cancer Cell”. In: *The Journal of Membrane Biology* 242.2 (2011), pp. 69–74. ISSN: 1432-1424. DOI: 10.1007/s00232-011-9381-7 (cit. on p. 15).
- [48] Julia Koehler Leman, Martin B Ulmschneider, and Jeffrey J Gray. “Computational modeling of membrane proteins”. In: *Proteins* 83.1 (Jan. 2015), pp. 1–24. ISSN: 0887-3585. DOI: 10.1002/prot.24703 (cit. on p. 16).
- [49] Marc A Martí-Renom et al. “Comparative Protein Structure Modeling of Genes and Genomes”. In: *Annual Review of Biophysics and Biomolecular Structure* 29.1 (June 2000), pp. 291–325. ISSN: 1056-8700. DOI: 10.1146/annurev.biophys.29.1.291 (cit. on p. 16).
- [50] Lars Malmström and David R Goodlett. “Protein structure modeling.” In: *Methods in molecular biology (Clifton, N.J.)* 673 (2010), pp. 63–72. ISSN: 1940-6029. DOI: 10.1007/978-1-60761-842-3_5 (cit. on p. 16).
- [51] A Sali and T L Blundell. “Comparative protein modelling by satisfaction of spatial restraints.” In: *Journal of molecular biology* 234.3 (Dec. 1993), pp. 779–815. ISSN: 0022-2836. DOI: 10.1006/jmbi.1993.1626 (cit. on p. 17).
- [52] Marco Biasini et al. “SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information”. In: *Nucleic Acids Research* 42.Web Server issue (July 2014), W252–W258. ISSN: 0305-1048. DOI: 10.1093/nar/gku340 (cit. on p. 17).
- [53] Johannes Söding, Andreas Biegert, and Andrei N Lupas. “The HHpred interactive server for protein homology detection and structure prediction”. In: *Nucleic Acids Research* 33.Web Server issue (July 2005), W244–W248. ISSN: 0305-1048. DOI: 10.1093/nar/gki408 (cit. on p. 17).

- [54] Jianyi Yang et al. “The I-TASSER Suite: protein structure and function prediction”. In: *Nat Meth* 12.1 (Jan. 2015), pp. 7–8. ISSN: 1548-7091 (cit. on p. 17).
- [55] Ambrish Roy, Alper Kucukural, and Yang Zhang. “I-TASSER: a unified platform for automated protein structure and function prediction”. In: *Nature protocols* 5.4 (Apr. 2010), pp. 725–738. ISSN: 1754-2189. DOI: 10.1038/nprot.2010.5 (cit. on p. 17).
- [56] Yang Zhang. “I-TASSER server for protein 3D structure prediction”. In: *BMC Bioinformatics* 9 (Jan. 2008), p. 40. ISSN: 1471-2105. DOI: 10.1186/1471-2105-9-40 (cit. on p. 17).
- [57] David E Kim, Dylan Chivian, and David Baker. “Protein structure prediction and analysis using the Robetta server”. In: *Nucleic Acids Research* 32.Web Server issue (July 2004), W526–W531. ISSN: 0305-1048. DOI: 10.1093/nar/gkh468 (cit. on p. 17).
- [58] Morten Källberg et al. “Protein Structure Prediction”. In: ed. by Daisuke Kihara. New York, NY: Springer New York, 2014. Chap. RaptorX se, pp. 17–27. ISBN: 978-1-4939-0366-5. DOI: 10.1007/978-1-4939-0366-5_2 (cit. on p. 17).
- [59] P A Bates et al. “Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM.” In: *Proteins Suppl* 5 (Jan. 2001), pp. 39–46. ISSN: 0887-3585 (cit. on p. 17).
- [60] G. Vriend. “WHAT IF: A molecular modeling and drug design program”. In: *Journal of Molecular Graphics* 8.1 (Mar. 1990), pp. 52–56. ISSN: 02637855. DOI: 10.1016/0263-7855(90)80070-V (cit. on p. 17).
- [61] Jane S. Richardson. *Advances in Protein Chemistry Volume 34*. Vol. 34. 1981, pp. 167–339. ISBN: 9780120342341. DOI: 10.1016/S0065-3233(08)60520-3 (cit. on p. 17).

- [62] Extracellular Proteins That and Modulate Cell-matrix Interactions. “Extracellular Proteins That”. In: 266.23 (1991), pp. 15–18 (cit. on p. 17).
- [63] D B Wetlaufer. “Nucleation, rapid folding, and globular intrachain regions in proteins.” In: *Proceedings of the National Academy of Sciences of the United States of America* 70.3 (1973), pp. 697–701. ISSN: 0027-8424. DOI: 10.1073/pnas.70.3.697 (cit. on p. 17).
- [64] Suhail A Islam et al. “Identification and analysis of domains in proteins presented to identify domains in proteins”. In: 8.6 (1995), pp. 513–525 (cit. on p. 17).
- [65] Jung-Hoon Han et al. “The folding and evolution of multidomain proteins.” In: *Nature reviews. Molecular cell biology* 8.4 (2007), pp. 319–330. ISSN: 1471-0072. DOI: 10.1038/nrm2144 (cit. on p. 17).
- [66] Cyrus Chothia et al. “Evolution of the protein repertoire.” In: *Science (New York, N.Y.)* 300.5626 (2003), pp. 1701–3. ISSN: 1095-9203. DOI: 10.1126/science.1085371 (cit. on p. 17).
- [67] Christine Vogel et al. “Structure, function and evolution of multidomain proteins”. In: *Current Opinion in Structural Biology* 14.2 (2004), pp. 208–216. ISSN: 0959440X. DOI: 10.1016/j.sbi.2004.03.011 (cit. on p. 17).
- [68] G Apic, J Gough, and S a Teichmann. “Domain combinations in archaeal, eubacterial and eukaryotic proteomes.” In: *Journal of molecular biology* 310.2 (2001), pp. 311–325. ISSN: 0022-2836. DOI: 10.1006/jmbi.2001.4776 (cit. on p. 17).
- [69] Alexey G. Murzin et al. “SCOP: A structural classification of proteins database for the investigation of sequences and structures”. In: *Journal of Molecular Biology* 247.4 (1995), pp. 536–540. ISSN: 00222836. DOI: 10.1016/S0022-2836(05)80134-2 (cit. on p. 17).

- [70] Ca Orengo et al. “CATH - a hierarchic classification of protein domain structures”. In: *Structure* March (1997), pp. 1093–1109. ISSN: 09692126. DOI: 10.1016/S0969-2126(97)00260-8 (cit. on p. 17).
- [71] A Bateman et al. “The Pfam protein families database”. In: *Nucleic Acids Research* 28.1 (2002), pp. 276–280. ISSN: 0305-1048 (Print) 0305-1048 (Linking). DOI: gkd038[pil] (cit. on p. 17).
- [72] Sarah Hunter et al. “InterPro: The integrative protein signature database”. In: *Nucleic Acids Research* 37.SUPPL. 1 (2009), pp. 211–215. ISSN: 03051048. DOI: 10.1093/nar/gkn785 (cit. on p. 17).
- [73] Friedrich Cramer. “Emil Fischer’s Lock and Key Hypothesis after 100 years towards a Supracellular Chemistry”. In: *Perspectives in Supramolecular Chemistry*. John Wiley & Sons, Ltd., 1994, pp. 1–23. ISBN: 9780470511411. DOI: 10.1002/9780470511411.ch1 (cit. on p. 18).
- [74] D E Koshland. “Enzyme flexibility and enzyme action”. In: *Journal of Cellular and Comparative Physiology* 54.S1 (Dec. 1959), pp. 245–258. ISSN: 1553-0809. DOI: 10.1002/jcp.1030540420 (cit. on p. 18).
- [75] Jacque Monod, Jeffries Wyman, and Jean-Pierre Changeux. “On the nature of allosteric transitions: A plausible model”. In: *Journal of Molecular Biology* 12.1 (May 1965), pp. 88–118. ISSN: 00222836. DOI: 10.1016/S0022-2836(65)80285-6 (cit. on p. 19).
- [76] Akio Kitao, Steven Hayward, and Nobuhiro Go. “Energy landscape of a native protein: Jumping among minima model”. In: *Proteins: Structure, Function, and Bioinformatics* 33.4 (Dec. 1998), pp. 496–517. ISSN: 1097-0134. DOI: 10.1002/(SICI)1097-0134(19981201)33:4<496::AID-PROT4>3.0.CO;2-1 (cit. on p. 19).

- [77] G A Petsko and D Ringe. “Fluctuations in Protein Structure from X-Ray Diffraction”. In: *Annual Review of Biophysics and Bioengineering* 13.1 (June 1984), pp. 331–371. ISSN: 0084-6589. DOI: 10.1146/annurev.bb.13.060184.001555 (cit. on p. 19).
- [78] J Foote and C Milstein. “Conformational isomerism and the diversity of antibodies.” In: *Proceedings of the National Academy of Sciences of the United States of America* 91.22 (Oct. 1994), pp. 10370–10374. ISSN: 0027-8424 (cit. on p. 19).
- [79] Leo C James, Pietro Roversi, and Dan S Tawfik. “Antibody Multispecificity Mediated by Conformational Diversity”. In: *Science* 299.5611 (Feb. 2003), pp. 1362–1367 (cit. on p. 19).
- [80] Michael F Dunn. “Protein-Ligand Interactions: General Description”. In: *eLS*. John Wiley & Sons, Ltd, 2001. ISBN: 9780470015902. DOI: 10.1038/npg.els.0001340 (cit. on p. 19).
- [81] Julien Michel, Julian Tirado-Rives, and William L Jorgensen. “Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization”. In: *Journal of the American Chemical Society* 131.42 (Oct. 2009), pp. 15403–15411. ISSN: 0002-7863. DOI: 10.1021/ja906058w (cit. on p. 22).
- [82] Krishna Ravindranathan et al. “Improving MM-GB SA Scoring through the Application of the Variable Dielectric Model”. In: *Journal of chemical theory and computation* 7.12 (Dec. 2011), pp. 3859–3865. ISSN: 1549-9618. DOI: 10.1021/ct200565u (cit. on p. 22).
- [83] Julien Michel, Marcel L Verdonk, and Jonathan W Essex. “Protein Ligand Binding Affinity Predictions by Implicit Solvent Simulations: A Tool for Lead Optimization”. In: *Journal of Medicinal Chemistry* 49.25 (Dec. 2006), pp. 7427–7439. ISSN: 0022-2623. DOI: 10.1021/jm061021s (cit. on p. 22).

- [84] Hao-Yang Liu, Sam Z Grinter, and Xiaoqin Zou. “Multiscale generalized Born modeling of ligand binding energies for virtual database screening”. In: *The journal of physical chemistry. B* 113.35 (Sept. 2009), pp. 11793–11799. ISSN: 1520-6106. DOI: 10.1021/jp901212t (cit. on p. 22).
- [85] Yipin Lu et al. “Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes”. In: *Journal of Chemical Information and Modeling* 47.2 (Mar. 2007), pp. 668–675. ISSN: 1549-9596. DOI: 10.1021/ci6003527 (cit. on p. 22).
- [86] Kim A Sharp and Barry. Honig. “Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation”. In: *The Journal of Physical Chemistry* 94.19 (Sept. 1990), pp. 7684–7692. ISSN: 0022-3654. DOI: 10.1021/j100382a068 (cit. on p. 22).
- [87] Donald Bashford and David A Case. “GENERALIZED BORN MODELS OF MACROMOLECULAR SOLVATION EFFECTS”. In: *Annual Review of Physical Chemistry* 51.1 (Oct. 2000), pp. 129–152. ISSN: 0066-426X. DOI: 10.1146/annurev.physchem.51.1.129 (cit. on p. 22).
- [88] Richard A. Friesner et al. “Glide: A New Approach for Rapid, Accurate Docking and Scoring”. In: *Journal of Medicinal Chemistry* 47.7 (2004), pp. 1739–1749. ISSN: 00222623. DOI: 10.1021/jm0306430. arXiv: arXiv:1011.1669v3 (cit. on pp. 22, 24).
- [89] Claudia Steffen et al. “TmoleX a graphical user interface for TURBOMOLE.” In: *Journal of computational chemistry* 31.16 (2010), pp. 2967–2970. ISSN: 1096-987X. DOI: 10.1002/jcc. arXiv: NIHMS150003 (cit. on p. 22).
- [90] Peter Csermely et al. “Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review”. In: *Pharmacology and Therapeutics* 138.3 (2013), pp. 333–

408. ISSN: 01637258. DOI: 10.1016/j.pharmthera.2013.01.016. arXiv: 1210.0330 (cit. on p. 23).
- [91] Philip Prathipati and Kenji Mizuguchi. “Systems Biology Approaches to a Rational Drug Discovery Paradigm”. In: *Current Topics in Medicinal Chemistry* 16.9 (), pp. 1009–1025 (cit. on p. 23).
- [92] A Patrícia Bento et al. “The ChEMBL bioactivity database: an update”. In: *Nucleic acids research* 42.Database issue (Jan. 2014), pp. D1083–90. ISSN: 0305-1048. DOI: 10.1093/nar/gkt1031 (cit. on p. 23).
- [93] Feng Zhu et al. “Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery”. In: *Nucleic Acids Research* 40.Database issue (Jan. 2012), pp. D1128–D1136. ISSN: 0305-1048. DOI: 10.1093/nar/gkr797 (cit. on p. 23).
- [94] Liegi Hu et al. “Binding MOAD (Mother Of All Databases).” In: *Proteins* 60.3 (Aug. 2005), pp. 333–40. ISSN: 1097-0134. DOI: 10.1002/prot.20512 (cit. on p. 23).
- [95] Tiqing Liu et al. “BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities”. In: *Nucleic Acids Research* 35.Database issue (Jan. 2007), pp. D198–D201. ISSN: 0305-1048. DOI: 10.1093/nar/gkl999 (cit. on p. 23).
- [96] Sunghwan Kim et al. “PubChem Substance and Compound databases”. In: *Nucleic Acids Research* 44.D1 (Jan. 2016), pp. D1202–D1213. DOI: 10.1093/nar/gkv951 (cit. on p. 23).
- [97] Yanli Wang et al. “PubChem BioAssay: 2014 update”. In: *Nucleic Acids Research* 42.Database issue (Jan. 2014), pp. D1075–D1082. ISSN: 0305-1048. DOI: 10.1093/nar/gkt978 (cit. on p. 23).

- [98] John J Irwin et al. “ZINC: A Free Tool to Discover Chemistry for Biology”. In: *Journal of Chemical Information and Modeling* 52.7 (July 2012), pp. 1757–1768. ISSN: 1549-9596. DOI: 10 . 1021/ci3001277 (cit. on p. 23).
- [99] Hernán Alonso, Andrey A. Bliznyuk, and Jill E. Gready. “Combining docking and molecular dynamic simulations in drug design”. In: *Medicinal Research Reviews* 26.5 (2006), pp. 531–568. ISSN: 01986325. DOI: 10 . 1002/med.20067 (cit. on p. 24).
- [100] Garrett M Morris et al. “AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility”. In: *Journal of computational chemistry* 30.16 (Dec. 2009), pp. 2785–2791. ISSN: 0192-8651. DOI: 10 . 1002/jcc.21256 (cit. on p. 24).
- [101] Oleg Trott and Arthur J Olson. “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading”. In: *Journal of computational chemistry* 31.2 (Jan. 2010), pp. 455–461. ISSN: 0192-8651. DOI: 10 . 1002/jcc.21334 (cit. on p. 24).
- [102] Todd J a. Ewing and Irwin D Kuntz. “Critical evaluation of search algorithms for automated molecular docking and database screening”. In: *Journal of Computational Chemistry* 18 (1997), pp. 1175–1189. ISSN: 0192-8651. DOI: 10 . 1002/ (SICI) 1096-987X (19970715) 18:9<1175::AID-JCC6>3.0.CO;2-O (cit. on p. 24).
- [103] Matthias Rarey et al. “A Fast Flexible Docking Method using an Incremental Construction Algorithm”. In: *Journal of Molecular Biology* 261.3 (Aug. 1996), pp. 470–489. ISSN: 0022-2836. DOI: <http://dx.doi.org/10.1006/jmbi.1996.0477> (cit. on p. 24).
- [104] G Jones et al. “Development and validation of a genetic algorithm for flexible docking.” In: *Journal of molecular biology* 267.3 (Apr. 1997), pp. 727–48. ISSN: 0022-2836. DOI: 10 . 1006/jmbi.1996.0897 (cit. on p. 24).

- [105] Julie R Schames et al. “Discovery of a novel binding trench in HIV integrase.” In: *Journal of medicinal chemistry* 47.8 (Apr. 2004), pp. 1879–81. ISSN: 0022-2623. DOI: 10.1021/jm0341913 (cit. on p. 24).
- [106] Istvan J Enyedy et al. “Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening”. In: *Journal of Medicinal Chemistry* 44.25 (Dec. 2001), pp. 4313–4324. ISSN: 0022-2623. DOI: 10.1021/jm010016f (cit. on p. 24).
- [107] Eric Vangrevelinghe et al. “Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking”. In: *Journal of Medicinal Chemistry* 46.13 (June 2003), pp. 2656–2662. ISSN: 0022-2623. DOI: 10.1021/jm030827e (cit. on p. 24).
- [108] D Kitchen et al. “Docking and scoring in virtual screening for drug discovery: methods and applications”. In: *Nature Reviews Drug Discovery* 3.11 (2004), pp. 935–949. ISSN: 1474-1784. DOI: 10.1038/nrd1549 (cit. on p. 24).
- [109] Sara Reardon. “Project ranks billions of drug interactions.” In: *Nature* 503.7477 (2013), pp. 449–50. ISSN: 1476-4687. DOI: 10.1038/503449a (cit. on p. 24).
- [110] J Drews. “Drug discovery: a historical perspective.” In: *Science* 287.5460 (2000), pp. 1960–64. ISSN: 0036-8075. DOI: 10.1126/science.287.5460.1960 (cit. on p. 25).
- [111] Graham L Patrick. “History of Drug Discovery”. In: *eLS*. John Wiley & Sons, Ltd, 2001. ISBN: 9780470015902. DOI: 10.1002/9780470015902.a0003090.pub2 (cit. on p. 25).
- [112] Lisa Hutchinson and Rebecca Kirk. “High drug attrition rates[mdash]where are we going wrong?” In: *Nat Rev Clin Oncol* 8.4 (Apr. 2011), pp. 189–190. ISSN: 1759-4774 (cit. on p. 26).
- [113] Mark A Lindsay. “Target discovery”. In: *Nat Rev Drug Discov* 2.10 (Oct. 2003), pp. 831–838. ISSN: 1474-1776 (cit. on p. 26).

- [114] J. P. Hughes et al. “Principles of early drug discovery”. In: *British Journal of Pharmacology* 162.6 (2011), pp. 1239–1249. ISSN: 00071188. DOI: 10.1111/j.1476-5381.2010.01127.x (cit. on p. 26).
- [115] Peter Imming, Christian Sinning, and Achim Meyer. “Drugs, their targets and the nature and number of drug targets.” In: *Nature reviews. Drug discovery* 5.10 (2006), pp. 821–834. ISSN: 1474-1776. DOI: 10.1038/nrd2132 (cit. on p. 26).
- [116] J E Klees and R Joines. “Occupational health issues in the pharmaceutical research and development process”. eng. In: *Occupational medicine (Philadelphia, Pa.)* 12.1 (1997), pp. 5–27. ISSN: 0885-114X (cit. on p. 26).
- [117] Steven M Paul et al. “How to improve R&D productivity: the pharmaceutical industry’s grand challenge.” In: *Nature reviews. Drug discovery* 9.3 (2010), pp. 203–214. ISSN: 1474-1776. DOI: 10.1038/nrd3078 (cit. on p. 27).
- [118] Jack W Scannell et al. “Diagnosing the decline in pharmaceutical R&D efficiency.” In: *Nature reviews. Drug discovery* 11.3 (2012), pp. 191–200. ISSN: 1474-1784. DOI: 10.1038/nrd3681 (cit. on p. 27).
- [119] Gregory Sliwoski et al. “Computational Methods in Drug Discovery”. In: January (2014), pp. 334–395 (cit. on p. 28).
- [120] Yongliang Yang, S. James Adelstein, and Amin I. Kassir. “Target discovery from data mining approaches”. In: *Drug Discovery Today* 14.3-4 (2009), pp. 147–154. ISSN: 13596446. DOI: 10.1016/j.drudis.2008.12.005 (cit. on p. 29).
- [121] *PREDICT: a method for inferring novel drug indications with application to personalized medicine* (cit. on p. 29).
- [122] M Zhang et al. “The orphan disease networks”. In: *Am J Hum Genet* 88 (2011). DOI: 10.1016/j.ajhg.2011.05.006 (cit. on p. 29).

- [123] D T Yutaka Fukuoka and O g. a. w. a. Hisamichi. “A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs”. In: *Bioinformatics* 9 (2013). DOI: 10 . 6026/97320630009089 (cit. on p. 29).
- [124] K Raman and N Chandra. “Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance”. In: *BMC Microbiology* 8 (2008) (cit. on pp. 29, 37–39).
- [125] Suthat Phaiphinit et al. “In silico multiple-targets identification for heme detoxification in the human malaria parasite *Plasmodium falciparum*”. In: *Infection, Genetics and Evolution* 37 (Jan. 2016), pp. 237–244. ISSN: 1567-1348. DOI: <http://dx.doi.org/10.1016/j.meegid.2015.11.025> (cit. on p. 29).
- [126] Jouhyun Jeon et al. “A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening”. In: *Genome Medicine* 6.7 (2014), pp. 1–18. ISSN: 1756-994X. DOI: 10 . 1186/s13073-014-0057-7 (cit. on p. 29).
- [127] Regina Augustin et al. “Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10”. In: *BMC Medical Genetics* 13.1 (2012), pp. 1–12. ISSN: 1471-2350. DOI: 10 . 1186/1471-2350-13-35 (cit. on p. 29).
- [128] Francisco Martínez-Jiménez et al. “Target Prediction for an Open Access Set of Compounds Active against *Mycobacterium tuberculosis*”. In: *PLoS Computational Biology* 9.10 (Oct. 2013). Ed. by Alexander Donald MacKerell, e1003253. ISSN: 1553-7358. DOI: 10 . 1371/journal.pcbi.1003253 (cit. on pp. 29, 38).
- [129] Roger Perkins et al. “Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology.” In: *En-*

- vironmental toxicology and chemistry / SETAC* 22.8 (2003), pp. 1666–1679. ISSN: 1092-874X. DOI: 10.1897/01-171 (cit. on p. 30).
- [130] Julie E Penzotti, Gregory A Landrum, and Santosh Putta. “Building predictive ADMET models for early decisions in drug discovery”. In: *Current opinion in drug discovery & development* 7.1 (Jan. 2004), pp. 49–61. ISSN: 1367-6733 (cit. on p. 30).
- [131] Olga Obrezanova et al. “Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties”. In: *Journal of Chemical Information and Modeling* 47.5 (Sept. 2007), pp. 1847–1857. ISSN: 1549-9596. DOI: 10.1021/ci7000633 (cit. on p. 30).
- [132] Fumitaka Yoshida and John G Topliss. “QSAR Model for Drug Human Oral Bioavailability”. In: *Journal of Medicinal Chemistry* 43.13 (June 2000), pp. 2575–2585. ISSN: 0022-2623. DOI: 10.1021/jm0000564 (cit. on p. 30).
- [133] Jitender Verma, Vijay M. Khedkar, and Evans C. Coutinho. “3D-QSAR in Drug Design”. In: *Current Topics in Medicinal Chemistry* 10.1 (2010), pp. 95–115. ISSN: 15680266. DOI: 10.2174/156802610790232260 (cit. on p. 30).
- [134] R D Cramer, D E Patterson, and J D Bunce. “Comparative molecular field analysis (CoMFA)”. In: *Journal of the American Chemical Society* 110.18 (1988), pp. 5959–5967. ISSN: 0002-7863. DOI: 10.1021/ja00226a005 (cit. on p. 30).
- [135] A J Hopfinger et al. “Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism”. In: *Journal of the American Chemical Society* 119.43 (Oct. 1997), pp. 10509–10524. ISSN: 0002-7863. DOI: 10.1021/ja9718937 (cit. on p. 30).
- [136] Sean Ekins et al. “Three-and Four-Dimensional Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2C9 Inhibitors”. In: *Drug Metabolism and Disposition* 28.8 (Aug. 2000), pp. 994–1002 (cit. on p. 30).

- [137] Manisha Iyer and A J Hopfinger. “Treating Chemical Diversity in QSAR Analysis Modeling Diverse HIV-1 Integrase Inhibitors Using 4D Fingerprints”. In: *Journal of Chemical Information and Modeling* 47.5 (Sept. 2007), pp. 1945–1960. ISSN: 1549-9596. DOI: 10.1021/ci700153g (cit. on p. 30).
- [138] Nelilma Correia Romeiro et al. “Construction of 4D-QSAR Models for Use in the Design of Novel p38-MAPK Inhibitors”. In: *Journal of Computer-Aided Molecular Design* 19.6 (), pp. 385–400. ISSN: 1573-4951. DOI: 10.1007/s10822-005-7927-4 (cit. on p. 30).
- [139] Carolina H. Andrade et al. “4D-QSAR: Perspectives in drug design”. In: *Molecules* 15.5 (2010), pp. 3281–3294. ISSN: 14203049. DOI: 10.3390/molecules15053281 (cit. on p. 30).
- [140] Angelo Vedani and Max Dobler. “5D-QSAR: The Key for Simulating Induced Fit”. In: *Journal of Medicinal Chemistry* 45.11 (May 2002), pp. 2139–2149. ISSN: 0022-2623. DOI: 10.1021/jm011005p (cit. on p. 31).
- [141] Angelo Vedani, Max Dobler, and Markus A Lill. “Combining Protein Modeling and 6D-QSAR. Simulating the Binding of Structurally Diverse Ligands to the Estrogen Receptor”. In: *Journal of Medicinal Chemistry* 48.11 (June 2005), pp. 3700–3703. ISSN: 0022-2623. DOI: 10.1021/jm050185q (cit. on p. 31).
- [142] Christopher A Lipinski. “Lead and drug-like compounds: the rule of five revolution.” In: *Drug discovery today. Technologies* 1.4 (Dec. 2004), pp. 337–41. ISSN: 1740-6749. DOI: 10.1016/j.ddtec.2004.11.007 (cit. on p. 31).
- [143] G Richard Bickerton et al. “Quantifying the chemical beauty of drugs.” en. In: *Nature chemistry* 4.2 (Feb. 2012), pp. 90–8. ISSN: 1755-4349. DOI: 10.1038/nchem.1243 (cit. on p. 31).

- [144] J      Besnard et al. “Automated design of ligands to polypharmacological profiles”. In: *Nature* 492.7428 (Dec. 2012), pp. 215–220. ISSN: 0028-0836. DOI: 10.1038/nature11691 (cit. on p. 32).
- [145] Clare M. Lewandowski, New Co-investigator, and Clare M. Lewandowski. “WHO Global tuberculosis report 2015”. In: *The effects of brief mindfulness intervention on acute pain experience: An examination of individual difference 1* (2015), pp. 1689–1699. ISSN: 1098-6596. DOI: 10.1017/CBO9781107415324.004. arXiv: arXiv:1011.1669v3 (cit. on pp. 32, 33, 35).
- [146] D W Connell et al. “Update on tuberculosis: TB in the early 21st century”. In: *European Respiratory Review* 20.120 (June 2011), pp. 71–84 (cit. on p. 32).
- [147] M Berry and O M Kon. “Multidrug- and extensively drug-resistant tuberculosis: an emerging threat”. In: *European Respiratory Review* 18.114 (Nov. 2009), pp. 195–197 (cit. on p. 32).
- [148] Patrice Trouiller et al. “Drug development for neglected diseases: a deficient market and a public-health policy failure”. In: *The Lancet* 359.9324 (June 2002), pp. 2188–2194. ISSN: 01406736. DOI: 10.1016/S0140-6736(02)09096-7 (cit. on pp. 32, 33).
- [149] Kim Lewis. “Platforms for antibiotic discovery”. In: *Nat Rev Drug Discov* 12.5 (May 2013), pp. 371–387. ISSN: 1474-1776 (cit. on p. 32).
- [150] J M Conly and B L Johnston. “Where are all the new antibiotics? The new antibiotic paradox”. In: *The Canadian Journal of Infectious Diseases & Medical Microbiology* 16.3 (Mar. 2005), pp. 159–160. ISSN: 1712-9532 (cit. on p. 33).
- [151] Losee L Ling et al. “A new antibiotic kills pathogens without detectable resistance”. In: *Nature* 517.7535 (2015), pp. 455–459. ISSN: 1476-4687. DOI: 10.1038/nature14098 (cit. on p. 33).

- [152] *Philanthropists unite to accelerate global fight against tuberculosis with combined \$20 million gift to Broad Institute* - <https://www.broadinstitute.org/news/6981> - (cit. on p. 33).
- [153] Deepak K Karki et al. “Costs of a successful public-private partnership for TB control in an urban setting in Nepal”. In: *BMC Public Health* 7.1 (2007), pp. 1–12. ISSN: 1471-2458. DOI: 10.1186/1471-2458-7-84 (cit. on p. 34).
- [154] K. J R Murthy et al. “Public-private partnership in tuberculosis control: Experience in Hyderabad, India”. In: *International Journal of Tuberculosis and Lung Disease* 5.4 (2001), pp. 354–359. ISSN: 10273719 (cit. on p. 34).
- [155] Xun Lei et al. “Public–private mix for tuberculosis care and control: a systematic review”. In: *International Journal of Infectious Diseases* 34 (May 2015), pp. 20–32. ISSN: 1201-9712. DOI: <http://dx.doi.org/10.1016/j.ijid.2015.02.015> (cit. on p. 35).
- [156] Edison S Zuniga, Julie Early, and Tanya Parish. “The future for early-stage tuberculosis drug discovery”. In: *Future Microbiology* 10.2 (2015), pp. 217–229. ISSN: 1746-0913. DOI: 10.2217/fmb.14.125 (cit. on p. 36).
- [157] P J Brennan. “Structure, function, and biogenesis of the cell wall of *Mycobacterium tuberculosis*”. In: *Tuberculosis* 83.1–3 (Feb. 2003), pp. 91–97. ISSN: 1472-9792. DOI: [http://dx.doi.org/10.1016/S1472-9792\(02\)00089-6](http://dx.doi.org/10.1016/S1472-9792(02)00089-6) (cit. on p. 36).
- [158] Liliana Rodrigues et al. “Contribution of efflux activity to isoniazid resistance in the *Mycobacterium tuberculosis* complex”. In: *Infection, Genetics and Evolution* 12.4 (June 2012), pp. 695–700. ISSN: 1567-1348. DOI: <http://dx.doi.org/10.1016/j.meegid.2011.08.009> (cit. on p. 36).

- [159] Ujjini H Manjunatha and Paul W Smith. “Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening”. In: *Bioorganic & Medicinal Chemistry* 23.16 (Aug. 2015), pp. 5087–5097. ISSN: 0968-0896. DOI: <http://dx.doi.org/10.1016/j.bmc.2014.12.031> (cit. on p. 36).
- [160] Lluís Ballell et al. “Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.” In: *ChemMedChem* 8.2 (Mar. 2013), pp. 313–21. ISSN: 1860-7187. DOI: [10.1002/cmdc.201200428](http://dx.doi.org/10.1002/cmdc.201200428) (cit. on p. 36).
- [161] Sae Woong Park et al. “Target-Based Identification of Whole-Cell Active Inhibitors of Biotin Biosynthesis in *Mycobacterium tuberculosis*”. In: *Chemistry & Biology* 22.1 (Jan. 2015), pp. 76–86. ISSN: 1074-5521. DOI: <http://dx.doi.org/10.1016/j.chembiol.2014.11.012> (cit. on p. 36).
- [162] Garima Arora et al. “High Throughput Screen Identifies Small Molecule Inhibitors Specific for *Mycobacterium tuberculosis* Phosphoserine Phosphatase”. In: *Journal of Biological Chemistry* (July 2014). DOI: [10.1074/jbc.M114.597682](http://dx.doi.org/10.1074/jbc.M114.597682) (cit. on p. 36).
- [163] Sean Ekins, Alex M Clark, and Malabika Sarker. “TB Mobile: a mobile app for anti-tuberculosis molecules with known targets”. In: *Journal of Cheminformatics* 5.1 (2013), pp. 1–14. ISSN: 1758-2946. DOI: [10.1186/1758-2946-5-13](http://dx.doi.org/10.1186/1758-2946-5-13) (cit. on pp. 37, 39).
- [164] Gregory J Crowther et al. “Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach”. In: *PLoS Negl Trop Dis* 4.8 (Aug. 2010), e804 (cit. on pp. 37, 38).
- [165] Sean Ekins et al. “A collaborative database and computational models for tuberculosis drug discovery.” In: *Molecular bioSystems* 6.5 (2010), pp. 840–851. ISSN: 1742-206X. DOI: [10.1039/b917766c](http://dx.doi.org/10.1039/b917766c) (cit. on pp. 37, 38).

- [166] Sarah L Kinnings et al. “Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis”. In: *PLoS Comput Biol* 5.7 (July 2009), e1000423 (cit. on pp. 37, 38).
- [167] Marc R de Jonge et al. “A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910”. In: *Proteins: Structure, Function, and Bioinformatics* 67.4 (June 2007), pp. 971–980. ISSN: 1097-0134. DOI: 10.1002/prot.21376 (cit. on pp. 37, 38).
- [168] Ashutosh Kumar and Mohammad Imran Siddiqi. “Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase”. In: *Journal of Molecular Modeling* 16.5 (2009), pp. 877–893. ISSN: 0948-5023. DOI: 10.1007/s00894-009-0584-0 (cit. on pp. 37, 39).
- [169] Jocelyne M Lew et al. “TubercuList – 10 years after”. In: *Tuberculosis* 91.1 (Jan. 2011), pp. 1–7. ISSN: 1472-9792. DOI: <http://dx.doi.org/10.1016/j.tube.2010.09.008> (cit. on pp. 37, 39).
- [170] Leandro Radusky et al. “TuberQ: a Mycobacterium tuberculosis protein druggability database”. In: *Database* 2014 (Jan. 2014). DOI: 10.1093/database/bau035 (cit. on pp. 37, 39).
- [171] Alex M. Clark, Malabika Sarker, and Sean Ekins. “New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0”. In: *Journal of Cheminformatics* 6.1 (2014), pp. 1–17. ISSN: 17582946. DOI: 10.1186/s13321-014-0038-2 (cit. on pp. 37, 39).
- [172] María Jose Rebollo-Lopez et al. “Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.” In: *PloS one* 10.12 (2015), e0142293. ISSN: 1932-6203. DOI: 10.1371/journal.pone.0142293 (cit. on p. 38).

- [173] International Agency for Research on Cancer. *World Cancer Report 2014*. Tech. rep. 2014 (cit. on p. 40).
- [174] A M Scott, J D Wolchok, and L J Old. “Antibody therapy of cancer”. In: *Nat Rev Cancer* 12.4 (2012), pp. 278–287. ISSN: 1474-1768. DOI: 10.1038/nrc3236 (cit. on pp. 40, 41).
- [175] Derek J Jonker et al. “Cetuximab for the Treatment of Colorectal Cancer”. In: *New England Journal of Medicine* 357.20 (Nov. 2007), pp. 2040–2048. ISSN: 0028-4793. DOI: 10.1056/NEJMoa071834 (cit. on p. 41).
- [176] Mohamedtaki A Tejani, Roger B Cohen, and Raneer Mehra. “The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer”. In: *Biologics : Targets & Therapy* 4 (Aug. 2010), pp. 173–185. ISSN: 1177-5475 (cit. on p. 41).
- [177] Michael A Postow, Margaret K Callahan, and Jedd D Wolchok. “Immune Checkpoint Blockade in Cancer Therapy”. In: *Journal of Clinical Oncology* (Jan. 2015). DOI: 10.1200/JCO.2014.59.4358 (cit. on p. 41).
- [178] Suzanne Demko et al. “FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia”. In: *The Oncologist* 13.2 (Feb. 2008), pp. 167–174. DOI: 10.1634/theoncologist.2007-0218 (cit. on p. 41).
- [179] Napoleone Ferrara et al. “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer”. In: *Nat Rev Drug Discov* 3.5 (May 2004), pp. 391–400. ISSN: 1474-1776 (cit. on p. 41).
- [180] Gillian M Keating. “Bevacizumab: A Review of Its Use in Advanced Cancer”. In: *Drugs* 74.16 (2014), pp. 1891–1925. ISSN: 1179-1950. DOI: 10.1007/s40265-014-0302-9 (cit. on p. 41).

- [181] Thomas E Witzig et al. “Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma”. In: *Journal of Clinical Oncology* 20.15 (Aug. 2002), pp. 3262–3269. DOI: 10 . 1200 / JCO . 2002 . 11 . 017 (cit. on p. 41).
- [182] Jianming Zhang, Priscilla L Yang, and Nathanael S Gray. “Targeting cancer with small molecule kinase inhibitors.” In: *Nature reviews. Cancer* 9.1 (2009), pp. 28–39. ISSN: 1474-175X. DOI: 10 . 1038 / nrc2559 (cit. on p. 42).
- [183] I Bernard Weinstein and Andrew K Joe. “Mechanisms of Disease: oncogene addiction, a rationale for molecular targeting in cancer therapy”. In: *Nat Clin Prac Oncol* 3.8 (Aug. 2006), pp. 448–457. ISSN: 1743-4254 (cit. on p. 42).
- [184] Paolo A Ascierto et al. “The role of BRAF V600 mutation in melanoma”. In: *Journal of Translational Medicine* 10 (July 2012), p. 85. ISSN: 1479-5876. DOI: 10 . 1186 / 1479 - 5876 - 10 - 85 (cit. on p. 42).
- [185] Gideon Bollag et al. “Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma”. In: *Nature* 467.7315 (Sept. 2010), pp. 596–599. ISSN: 0028-0836. DOI: 10 . 1038 / nature09454 (cit. on p. 42).
- [186] Geoffrey T Gibney and Jonathan S Zager. “Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies”. In: *Expert Opinion on Drug Metabolism & Toxicology* 9.7 (July 2013), pp. 893–899. ISSN: 1742-5255. DOI: 10 . 1517 / 17425255 . 2013 . 794220 (cit. on p. 42).
- [187] Keith T Flaherty et al. “Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations”. In: *New England Journal of Medicine* 367.18 (Sept. 2012), pp. 1694–1703. ISSN: 0028-4793. DOI: 10 . 1056 / NEJMoa1210093 (cit. on p. 43).

- [188] Keith T Flaherty et al. “Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma”. In: *New England Journal of Medicine* 367.2 (June 2012), pp. 107–114. ISSN: 0028-4793. DOI: 10.1056/NEJMoal203421 (cit. on p. 43).
- [189] S. Percy Ivy, Jeannette Y. Wick, and Bennett M. Kaufman. “An overview of small-molecule inhibitors of VEGFR signaling.” In: *Nature reviews. Clinical oncology* 6.10 (2009), pp. 569–79. ISSN: 1759-4782. DOI: 10.1038/nrclinonc.2009.130 (cit. on p. 43).
- [190] Caitriona Holohan et al. “Cancer drug resistance: an evolving paradigm.” In: *Nature reviews. Cancer* 13.10 (Oct. 2013), pp. 714–26. ISSN: 1474-1768. DOI: 10.1038/nrc3599 (cit. on pp. 43, 50).
- [191] G Manning. “The Protein Kinase Complement of the Human Genome”. In: *Science* 298.5600 (2002), pp. 1912–1934. ISSN: 00368075. DOI: 10.1126/science.1075762 (cit. on pp. 43, 49).
- [192] Susanne Müller et al. “The ins and outs of selective kinase inhibitor development”. In: *NATURE CHEMICAL BIOLOGY* www.nature.com/naturechemical 11.11 (2015), pp. 818–821. ISSN: 1552-4450. DOI: 10.1038/nchembio.1938 (cit. on pp. 43, 47).
- [193] Y. Liu et al. “A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src”. In: *Bioorganic & Medicinal Chemistry* 6.8 (1998), pp. 1219–1226. ISSN: 09680896. DOI: 10.1016/S0968-0896(98)00099-6 (cit. on p. 44).
- [194] Martin E M Noble, Jane A Endicott, and Louise N Johnson. “Protein Kinase Inhibitors: Insights into Drug Design from Structure”. In: *Science* 303.5665 (Mar. 2004), pp. 1800–1805 (cit. on p. 45).
- [195] Kinase Inhibitor et al. “Exploration of Type II Binding Mode : A Privileged Approach for”. In: (2016). DOI: 10.1021/cb500129t (cit. on p. 45).

- [196] Cristiano R W Guimarães et al. “Understanding the Impact of the P-loop Conformation on Kinase Selectivity”. In: *Journal of Chemical Information and Modeling* 51.6 (June 2011), pp. 1199–1204. ISSN: 1549-9596. DOI: 10.1021/ci200153c (cit. on p. 46).
- [197] Erick J Morris et al. “Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors”. In: *Cancer Discovery* 3.7 (July 2013), pp. 742–750. DOI: 10.1158/2159-8290.CD-13-0070 (cit. on p. 46).
- [198] Michael S Cohen et al. “Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors”. In: *Science* 308.5726 (May 2005), pp. 1318–1321 (cit. on p. 47).
- [199] Michele H Potashman and Mark E Duggan. “Covalent Modifiers: An Orthogonal Approach to Drug Design”. In: *Journal of Medicinal Chemistry* 52.5 (Mar. 2009), pp. 1231–1246. ISSN: 0022-2623. DOI: 10.1021/jm8008597 (cit. on p. 47).
- [200] Qingsong Liu et al. “Developing irreversible inhibitors of the protein kinase cysteinome”. In: *Chemistry & biology* 20.2 (Feb. 2013), pp. 146–159. ISSN: 1074-5521. DOI: 10.1016/j.chembiol.2012.12.006 (cit. on p. 47).
- [201] Tjeerd Barf and Allard Kaptein. “Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks”. In: *Journal of medicinal chemistry* 55 (2012), pp. 6243–6262. DOI: 10.1021/jm3003203 (cit. on p. 47).
- [202] Daniel C Liebler. “Protein Damage by Reactive Electrophiles: Targets and Consequences”. In: *Chemical Research in Toxicology* 21.1 (Jan. 2008), pp. 117–128. ISSN: 0893-228X. DOI: 10.1021/tx700235t (cit. on p. 47).
- [203] Kiyoshi Okamoto et al. “Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization”. In: *ACS Medicinal Chemistry Letters* 6.1 (Jan. 2015), pp. 89–94. ISSN: 1948-5875. DOI: 10.1021/ml500394m (cit. on p. 48).

- [204] Mindy I Davis et al. “Comprehensive analysis of kinase inhibitor selectivity”. In: *Nat Biotech* 29.11 (Nov. 2011), pp. 1046–1051. ISSN: 1087-0156 (cit. on p. 49).
- [205] Jianming Zhang, Priscilla L Yang, and Nathanael S Gray. “Targeting cancer with small molecule kinase inhibitors”. In: *Nat Rev Cancer* 9.1 (Jan. 2009), pp. 28–39. ISSN: 1474-175X (cit. on p. 49).
- [206] Scott W Lowe, Enrique Cepero, and Gerard Evan. “Intrinsic tumour suppression”. In: *Nature* 432.7015 (Nov. 2004), pp. 307–315. ISSN: 0028-0836 (cit. on p. 50).
- [207] Jeremy S. Logue and Deborah K. Morrison. “Complexity in the signaling network: Insights from the use of targeted inhibitors in cancer therapy”. In: *Genes and Development* 26.7 (2012), pp. 641–650. ISSN: 08909369. DOI: 10.1101/gad.186965.112 (cit. on p. 50).
- [208] Douglas W McMillin, Joseph M Negri, and Constantine S Mitsiades. “The role of tumour-stromal interactions in modifying drug response: challenges and opportunities”. In: *Nat Rev Drug Discov* 12.3 (Mar. 2013), pp. 217–228. ISSN: 1474-1776 (cit. on p. 50).
- [209] Sabine Maier et al. “Identifying DNA Methylation Biomarkers of Cancer Drug Response”. In: *American Journal of Pharmacogenomics* 5.4 (2005), pp. 223–232. ISSN: 1175-2203. DOI: 10.2165/00129785-200505040-00003 (cit. on p. 50).
- [210] Pasi Koivisto et al. “Androgen Receptor Gene Amplification: A Possible Molecular Mechanism for Androgen Deprivation Therapy Failure in Prostate Cancer”. In: *Cancer Research* 57.2 (Jan. 1997), pp. 314–319 (cit. on p. 51).
- [211] Michael W. Schmitt, Lawrence A. Loeb, and Jesse J. Salk. “The influence of subclonal resistance mutations on targeted cancer therapy.” In: *Nature reviews. Clinical oncology* (2015). ISSN: 1759-4782. DOI: 10.1038/nrclinonc.2015.175 (cit. on pp. 51, 52).

- [212] Yi-fan Chen and Li-wu Fu. “Mechanisms of acquired resistance to tyrosine kinase inhibitors”. In: *Acta Pharmaceutica Sinica B* 1.4 (Dec. 2011), pp. 197–207. ISSN: 2211-3835. DOI: <http://dx.doi.org/10.1016/j.apsb.2011.10.007> (cit. on p. 51).
- [213] Rina Barouch-Bentov and Karsten Sauer. “Mechanisms of Drug-Resistance in Kinases”. In: *Expert opinion on investigational drugs* 20.2 (Feb. 2011), pp. 153–208. ISSN: 1354-3784. DOI: [10.1517/13543784.2011.546344](https://doi.org/10.1517/13543784.2011.546344) (cit. on p. 51).
- [214] Mercedes E Gorre et al. “Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification”. In: *Science* 293.5531 (Aug. 2001), pp. 876–880 (cit. on p. 51).
- [215] Simona Soverini et al. “Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia”. In: *Leukemia Research* 38.1 (July 2016), pp. 10–20. ISSN: 0145-2126. DOI: [10.1016/j.leukres.2013.09.011](https://doi.org/10.1016/j.leukres.2013.09.011) (cit. on p. 51).
- [216] Jin-Yuan Shih, Chien-Hung Gow, and Pan-Chyr Yang. “EGFR Mutation Conferring Primary Resistance to Gefitinib in Non-Small-Cell Lung Cancer”. In: *New England Journal of Medicine* 353.2 (July 2005), pp. 207–208. ISSN: 0028-4793. DOI: [10.1056/NEJM200507143530217](https://doi.org/10.1056/NEJM200507143530217) (cit. on p. 51).
- [217] Annette O Walter et al. “Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC”. In: *Cancer Discovery* 3.12 (Dec. 2013), pp. 1404–1415. DOI: [10.1158/2159-8290.CD-13-0314](https://doi.org/10.1158/2159-8290.CD-13-0314) (cit. on p. 51).
- [218] Darren A E Cross et al. “AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer”. In: *Cancer discovery* 4.9 (Sept. 2014), pp. 1046–1061. ISSN: 2159-8274. DOI: [10.1158/2159-8290.CD-14-0337](https://doi.org/10.1158/2159-8290.CD-14-0337) (cit. on p. 51).

- [219] Dalia Ercan et al. “EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors”. In: *American Association for Cancer Research* 21.17 (Aug. 2015), pp. 3913–3923 (cit. on p. 52).
- [220] Robert C Doebele et al. “Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer”. In: *Clinical cancer research : an official journal of the American Association for Cancer Research* 18.5 (Mar. 2012), pp. 1472–1482. ISSN: 1078-0432. DOI: 10.1158/1078-0432.CCR-11-2906 (cit. on p. 52).
- [221] Alice T Shaw et al. “Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F”. In: *New England Journal of Medicine* 374.1 (Dec. 2015), pp. 54–61. ISSN: 0028-4793. DOI: 10.1056/NEJMoa1508887 (cit. on p. 52).
- [222] Jingjing Wu, John Savooji, and Delong Liu. “Second- and third-generation ALK inhibitors for non-small cell lung cancer”. In: *Journal of Hematology {&} Oncology* 9.1 (2016), pp. 1–7. ISSN: 1756-8722. DOI: 10.1186/s13045-016-0251-8 (cit. on p. 52).